

Article

Convenient Synthesis of *N*-Heterocycle-Fused Tetrahydro-1,4-diazepinones

Karolina Dzedulionytė ¹, Melita Veikšaitė ¹, Vít Morávek ², Vida Malinauskienė ¹, Greta Račkauskienė ³, Algirdas Šačkus ^{1,3}, Asta Žukauskaitė ^{1,2,*} and Eglė Arbačiauskienė ^{1,*}

¹ Department of Organic Chemistry, Kaunas University of Technology, Radvilėnu pl. 19A, LT-50254 Kaunas, Lithuania

² Department of Chemical Biology, Palacký University, Šlechtitelů 27, CZ-78371 Olomouc, Czech Republic

³ Institute of Synthetic Chemistry, Kaunas University of Technology, K. Baršausko g. 59, LT-51423 Kaunas, Lithuania

* Correspondence: asta.zukauskaite@upol.cz (A.Ž.); egle.arbaciauskiene@ktu.lt (E.A.)

Abstract: A general approach towards the synthesis of tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-one, tetrahydro[1,4]diazepino[1,2-*a*]indol-1-one and tetrahydro-1*H*-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one derivatives was introduced. A regioselective strategy was developed for synthesizing ethyl 1-(oxiran-2-ylmethyl)-1*H*-pyrazole-5-carboxylates from easily accessible 3(5)-aryl- or methyl-1*H*-pyrazole-5(3)-carboxylates. Obtained intermediates were further treated with amines resulting in oxirane ring-opening and direct cyclisation—yielding target pyrazolo[1,5-*a*][1,4]diazepin-4-ones. A straightforward two-step synthetic approach was applied to expand the current study and successfully functionalize ethyl 1*H*-indole- and ethyl 1*H*-benzo[*d*]imidazole-2-carboxylates. The structures of fused heterocyclic compounds were confirmed by ¹H, ¹³C, and ¹⁵N-NMR spectroscopy and HRMS investigation.

Keywords: pyrazole; indole; benzimidazole; fused *N*-heterocycles; regioselective *N*-alkylation; oxirane ring-opening; cyclisation



Citation: Dzedulionytė, K.; Veikšaitė, M.; Morávek, V.; Malinauskienė, V.; Račkauskienė, G.; Šačkus, A.; Žukauskaitė, A.; Arbačiauskienė, E. Convenient Synthesis of *N*-Heterocycle-Fused Tetrahydro-1,4-diazepinones.

Molecules **2022**, *27*, 8666.

<https://doi.org/10.3390/molecules27248666>

Academic Editors: Vera L. M. Silva and Artur M. S. Silva

Received: 15 November 2022

Accepted: 6 December 2022

Published: 7 December 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Nitrogen-based heterocyclic compounds are integrated into everyday life, including pharmaceuticals [1–3], agrochemicals [4,5], various plastics [6,7], dyes [8,9], and other functional materials [10–13]. When it comes to drug discovery, the development of effective and inexpensive active ingredients is one of the main goals of researchers in the field of medicinal chemistry. Over the years, great attention has been paid to fused heterocyclic derivatives, which are versatile molecules, exhibiting a wide variety of biological properties including antioxidant, antimicrobial, antiproliferative and other activities [14–17]. For example, fused pyrano[2,3-*c*]pyrazole derivatives **I** were designed, synthesized and have been identified as prospective COX-2 inhibitors (Figure 1) [18]. A more recent study by Wang et al. encompasses a discovery of novel pyrrolo[3,4-*c*]pyrazol-3-carboxamides, where lead compound **II** exhibited potent inhibition towards H⁺/K⁺-ATPase and in vivo histamine-stimulated gastric acid secretion [19]. In the field of indole-based chemistry, Feng et al. reported 9*H*-pyrimido[4,5-*b*]indol-4-amines **III** as promising non-toxic hematopoietic stem cells ex vivo expansion agents [20]. In the study of Purgatorio and co-workers, azepino[4,3-*b*]indole **IV** was found to be a useful and versatile scaffold for developing new small molecules inhibiting BChE, which is a promising drug target in severe Alzheimer's disease [21]. Fused systems with two 1,4-distanced nitrogen atoms encompass a variety of biological activities. For instance, Conde-Ceide et al. reported series of 6,7-dihydropyrazolo[1,5-*a*]pyrazin-4-one derivatives, such as **V**, as mGlu₅ receptor-positive allosteric modulators with efficacy in preclinical models of schizophrenia [22], whereas 2,3-dihydropyrazino[1,2-*a*]indole-1,4-dione derivatives **VI** were reported to act as dual EGFR/BRAF^{V600E} inhibitors [23]. Among

a variety of condensed systems, fusion of diazepine with selected heterocycles is important as it represents the most significant class of compounds in terms of clinical use [24]. Another notable example includes 5,6,7,8-tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepine-2-carboxamide **VII** as a non-nucleoside inhibitor of the respiratory syncytial virus (RSV) polymerase complex [25] (Figure 1).




Figure 1. Biologically relevant fused heterocyclic derivatives.

Combining the azaheterocycle scaffold into one structure with the diazepinone motif has been shown to result in biologically active compounds. However, to date examples of biologically active pyrazole-, pyrrole-, indole- and benzo[*d*]imidazole-fused diazepinone derivatives are limited. For example, tricyclic indole-diazepinones **VIII** inhibit induced myeloid leukaemia cell differentiation protein (Mcl-1) [26,27]. Chiral ferrocenylpyrazolo[1,5-*a*][1,4]diazepin-4-one **IX** was reported to suppress the growth of A549 lung cancer cells through cell cycle arrest, and H322 together with H1299 lung cancer cells by inducing apoptosis [28]. On the other hand, pyrrole or indole-fused diazepinones **X–XII** demonstrated inhibitory activity of various kinases, namely, extracellular signal-regulated kinase 2 (ERK2) [29], ribosomal S6 kinase (RSK) [30,31], cyclin-dependent kinase 1 (CDK1), and cyclin-dependent kinase 5 (CDK5) [32]. The abovementioned fused systems are not very widely investigated; therefore, it may be a promising entry in the field of synthetic and medicinal chemistry.

In our previous studies, we investigated the synthesis and biological activity of various annulated pyrazole systems such as substituted 2*H*-pyrazolo[4,3-*c*]pyridines [33–35],


benzopyrano[2,3-*c*]pyrazol-4(2*H*)-ones [36], 2*H*-furo[2,3-*c*]pyrazole ring systems [37], and others. In continuation of our previous research on fused heterocycles, herein we report an efficient two-step synthesis of tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones, tetrahydro[1,4]diazepino[1,2-*a*]indol-1-ones and tetrahydro-1*H*-benzo[4,5]imidazo[1,2-*a*][1,4]-diazepin-1-ones.

2. Results and Discussion

It is known that NH-pyrazoles usually exhibit annular *N,N*-prototropy [38,39]. *N*-Alkylation of asymmetrically ring-substituted 1*H*-pyrazoles generally results in the formation of a mixture of regioisomeric *N*-substituted products [40–43] and therefore regioselective *N*-alkylation requires optimization of reaction conditions [44]. Wright et al. has reported that alkylation of ethyl 1*H*-pyrazole-3(5)-carboxylate in the presence of K_2CO_3 was found to favor the formation of ethyl 1-substituted pyrazole-3-carboxylates while the formation of 1-substituted-1*H*-pyrazole-5-carboxylates could be sterically redirected by alkylating ethyl 3-(triphenylsilyl)-1*H*-pyrazole-5-carboxylate and removing the triphenylsilyl group with Bu_4NF [45]. In another study implemented by Xu et al., regioselective *N*-alkylation of NH-pyrazoles was accessed by using $MgBr_2$ and *i*- Pr_2NEt or K_2CO_3 and leading to the formation of different regioisomers [46,47].

In this work, the formation of the desired 1-(oxiran-2-ylmethyl)-3-aryl-1*H*-pyrazole-5-carboxylates by alkylation of easily accessible NH-pyrazoles [48] with 2-(chloromethyl)oxirane was optimized using **1a** as a model compound. As shown in Table 1, reaction outcome is highly dependent on the choice of the base and the solvent. First, application of different bases in solvent-free conditions was investigated. When ethyl 3-phenyl-1*H*-pyrazole-5-carboxylate **1a** was treated with 2-(chloromethyl)oxirane in the presence of K_2CO_3 at 70 °C (Entry 1) [49], a full conversion of **1a** was only achieved after 16 h affording regioisomer **2a** in 24% yield. Reaction using Cs_2CO_3 as a base at lower temperature (Entry 2) [50] proceeded giving isomers **2a** and **3a** in 3:2 ratio. Interestingly, when reaction was conducted using NaH (Entry 3), it proved to proceed in high regioselectivity. However, as the major product the undesired 5-phenyl-1*H*-pyrazole-3-carboxylate **3a** was obtained. Reaction with KOH in the presence of a catalytic amount of TBAB [51] also did not provide an increase in the yield of desired regioisomer **2a** (Entry 4).

Table 1. Optimization of reaction conditions to access **2a**.




Entry	2-(Chloromethyl)oxirane	Base	Solvent	Temp.	Time	Yield	
						2a	3a
1	15 eq	1.5 eq K_2CO_3	neat	70 °C	16 h	24%	-
2	10 eq	1.1 eq Cs_2CO_3	neat	40 °C	5 h	30%	20%
3	10 eq	1.3 eq NaH	neat	40 °C	5 h	-	50%
4 ^a	11.5 eq	2.0 eq KOH	neat	40 °C	6 h	7%	33%
5	5 eq	3.0 eq Cs_2CO_3	DMF	50 °C	24 h	49%	6%
6	1.5 eq	1.5 eq NaH	DMF	40 °C	5 h	50%	-
7	2.6 eq	1.4 eq Cs_2CO_3	ACN	reflux	5 h	45%	-

^a TBAB was used as a phase transfer catalyst.

Subsequently, alkylation reaction conditions were investigated in the presence of solvent. To our satisfaction, both Cs_2CO_3 (Entry 5) [52] and NaH (Entry 6) in DMF [53] provided desired isomer **2a** as the major product in high regioselectivity. An attempt to perform reaction in refluxing ACN using Cs_2CO_3 as a base [54] gave similar results (Entry 7). Interestingly, we noticed that alkylation using NaH proved to be highly regioselective as

the ratio of obtained products was drastically shifted by changing the reaction media. The use of DMF as a solvent in the presence of NaH was selected as the most suitable approach to synthesize ethyl 1-(oxiran-2-ylmethyl)-3-phenyl-1*H*-pyrazole-5-carboxylates **2a–h** as it required overall reduced reaction time and temperature for full conversion of pyrazoles **1a–h** (Scheme 1). Although the reactions exhibit high regioselectivity, obtained yields did not exceed 53–61% due to instability of products **2a–e** during the purification process.



Scheme 1. Synthesis of tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones **4a–x** via *N*-alkylation and subsequent cyclisation reactions.

Differentiation between major **2a** and minor **3a** isomers was implemented based on ¹H, ¹³C-HSQC, ¹H, ¹H-NOESY, ¹H, ¹³C- and ¹H, ¹⁵N-HMBC experimental data. For example, ¹H, ¹³C-HMBC experiment of regioisomer **2a** revealed 3-bond correlation between NCH₂ protons at δ 4.83 ppm and C-5 of pyrazole ring at δ 134.3 ppm (Figure 2). In the ¹H, ¹⁵N-HMBC spectrum, the same NCH₂ protons exhibited 2-bond correlation with N-1 pyrrole-like (δ −173.3 ppm) and 3-bond correlation with N-2 pyridine-like (δ −64.4 ppm) nitrogen atoms. The ¹H, ¹H-NOESY spectrum indicated close-in-space proton interaction between phenyl ring 2′(6′)-protons (δ 7.81 ppm) and pyrazole 4-*H* proton at δ 7.15 ppm.




Figure 2. Relevant ¹H-¹³C-HSQC, ¹H, ¹³C-HMBC, ¹H, ¹H-NOESY correlations and ¹H NMR (red), ¹³C NMR (italic), ¹⁵N NMR (blue) chemical shifts of regioisomers **2a** and **3a**.

The structure of minor regioisomer **3a** was elucidated in a similar manner. The ¹H, ¹³C-HMBC spectrum indicated that NCH₂ protons correlate with pyrazole C-5 carbon

at -146.2 ppm. Unambiguous distinction amongst both regioisomers can be determined using the $^1\text{H}, ^1\text{H}$ -NOESY experiment. Close-in-space proton interaction was observed between phenyl ring 2'(6')-H protons and pyrazole 4-H proton at δ 6.84 ppm, whereas regioisomer **3a** additionally exhibited NOEs between aromatic phenyl ring 2'(6')-protons and NCH_2 protons at δ 4.26–4.47 ppm.

According to the synthetic strategy, ethyl 1-(oxiran-2-ylmethyl)-3-aryl-1*H*-pyrazole-5-carboxylates **2a–h** were further used to obtain novel fused pyrazole-diazepinone systems via oxirane ring-opening. Due to high ring-strain, epoxides are prone to undergoing ring-opening reactions upon treatment with various nucleophiles [55] alone, or under the use of transition metal or organocatalysts [56–58]. On the other side, small heterocycles are also able to react with diverse electrophiles, affording a variety of functionalized molecules. Unlike the nucleophilic ring-opening reactions, the electrophilic ring-opening of small heterocycles cannot proceed by itself [59]. Methods reported in the literature for the epoxide ring-opening with amines are mainly focused on reactions mediated by a range of catalysts, activators, and promoters, in either solvent or solvent-free media [55,60–63]. In our study, intermediates **2a–h** were treated with various primary amines or ammonia in methanol (Scheme 1). Reaction monitoring indicated that ring closure proceeds rapidly to form a 1,4-diazepinone ring fused to pyrazole as no intermediate or side products have been observed, as opposed to the study reported by Shen et al. [28]. Reactions with primary amines, such as 2-methoxyethyl-, allyl- and benzylamines, afforded pyrazole-diazepinones **4i–x** in good to excellent yields (70–98%), while reactions with ammonia gave derivatives **4a–e** in substantially lower yields of 34–56%. Interestingly, tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones **4g,h** bearing a methyl substituent in either 2- or 3-position as well as 2,3-unsubstituted pyrazole **4f** were obtained in higher yields (70–91%) compared to their phenyl-substituted counterparts **4a–e**.

A possible pyrazole-fused 1,4-diazepinone formation mechanism involves an amine-induced $\text{S}_{\text{N}}2$ ring-opening at the less sterically hindered site of the oxirane ring [64]. Formed primary or secondary amine rapidly reacts with carbonyl carbon of an ester group, resulting in fused intermediate which further undergoes deprotonation and alkoxy group elimination to form final tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones **4a–x**.

To substantiate the structures of novel compounds, an unambiguous assignment of chemical shifts was carried out by investigating combined NMR spectroscopic data, i.e., $^1\text{H}, ^{13}\text{C}$ -HSQC, $^1\text{H}, ^{13}\text{C}$ -HMBC, $^1\text{H}, ^{15}\text{N}$ -HMBC and $^1\text{H}, ^1\text{H}$ -NOESY. In principle, cyclisation of ethyl 1-(oxiran-2-ylmethyl)-1*H*-pyrazole-5-carboxylate **2a** with ammonia could form two different isomers **4a** and **4a'** (Figure 3). The $^1\text{H}, ^{13}\text{C}$ -HMBC experiment revealed a three-bond correlation between NH proton at δ 8.24–8.31 ppm and C-3a carbon at δ 139.4 ppm. Moreover, the same NH proton exhibited strong three-bond connectivity with tertiary C-7 carbon at 69.4 ppm. Interactions between C-4 carbon and 3-H at δ 7.16 ppm as well as 6- H_aH_b protons were observed. Strong three-bond connectivity was observed in the $^1\text{H}, ^{15}\text{N}$ -HMBC spectrum between 7-H proton and pyrrole-like nitrogen atom N-9 at δ -175.4 ppm. In case of putative isomer **4a'**, the heteronuclear multiple bond correlations between NH proton and secondary aliphatic carbons should be observed. Furthermore, C-4 carbon would not exhibit three-bond correlation with aliphatic protons connected to a secondary carbon atom.

A brief experiment was performed with minor regioisomer **3a** in order to investigate if cyclisation reaction is possible when carboxylate and oxirane fragments are distanced via an additional nitrogen atom. Ethyl 1*H*-pyrazole-3-carboxylate **3a** was treated with either ammonia or benzyl amine; however, analysis of LC/MS and NMR data indicated that both reactions resulted in the oxirane ring opening without subsequent cyclisation.






Figure 3. Determination of possible isomeric structures **4a** and **4a'**. Relevant ¹H,¹³C-HMBC correlations and ¹H NMR, ¹³C NMR (italic), ¹⁵N NMR (in blue) chemical shifts of compound **4a**.

Subsequently, we sought to investigate the reactivity of ethyl 1*H*-indole-2-carboxylate **5a–e** and benzo[*d*]imidazole-2-carboxylate **5f** scaffolds and derive target tetrahydro[1,4]diazepino[1,2-*a*]indol-1-ones and tetrahydro-1*H*-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one utilizing the same straightforward 2-step approach (Scheme 2). *N*-Alkylation of **5a** with 2-(chloromethyl)oxirane using NaH in DMF at 40 °C provided ethyl 1-(oxiran-2-ylmethyl)-1*H*-indole-2-carboxylate **6a** in 54% yield. To increase the yield of target intermediate, several attempts to optimize reaction conditions were undertaken (Table 2). Unfortunately, neither elevation of reaction temperature, nor change of base or solvent have significant impact on the reaction outcome (Entries 2–5). Finally, the use of KOH base in DMF resulted not only in higher reactivity of starting 1*H*-indole-2-carboxylate **5a** (Entry 5) but also suppressed the formation of side products. Conditions utilizing the KOH-DMF system were applied to obtain ethyl 1-(oxiran-2-ylmethyl)-1*H*-indole-2-carboxylates **6a–e** in 39–75% yields (Scheme 2).



Scheme 2. Synthesis of 4-hydroxy-2,3,4,5-tetrahydro-1*H*-[1,4]diazepino[1,2-*a*]indol-1-ones **7a–f** and 4-hydroxy-2,3,4,5-tetrahydro-1*H*-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one **7g** via 2-step approach. *N*-Alkylation conditions: (a) 2-(chloromethyl)oxirane, KOH, DMF, 40 °C, 1 h (for **5a–e**); (b) 2-(chloromethyl)oxirane, NaH, DMF, 60 °C, 4 h (for **5f**).


Table 2. Optimization of reaction conditions between 5a and 2-(chloromethyl)oxirane.


Entry	2-(Chloromethyl)oxirane	Base	Solvent	Temp.	Time	Yield
1	1.5 eq	1.0 eq NaH	DMF	40 °C	5 h	54%
2	1.5 eq	1.0 eq NaH	DMF	60 °C	4 h	48%
3	1.2 eq	2.0 eq K ₂ CO ₃	DMF	90 °C	4 h	40%
4	1.5 eq	2.0 eq K ₂ CO ₃	DMF	90 °C	4 h	63%
5	1.5 eq	1.0 eq NaH	DMSO	40 °C	6 h	59%
6	1.5 eq	3.0 eq KOH	DMF	40 °C	1 h	73%

Interestingly, in the case benzo[*d*]imidazole-2-carboxylate 5f, optimized conditions using KOH were not efficient as alkylation product was not obtained, suggesting lower reactivity of the NH group of this compound. Fortunately, *N*-alkylation of benzo[*d*]imidazole-2-carboxylate 5f was accomplished under primary optimized conditions utilizing NaH-DMF at 60 °C, giving rise to target intermediate 6f in 33% yield as other alkylation conditions did not provide a better result.

In the next step, applicability of direct ring opening-cyclisation reaction was investigated. Ethyl 1-(oxiran-2-ylmethyl)-1*H*-indole-2-carboxylates 6a–e and ethyl 1-(oxiran-2-ylmethyl)-1*H*-benzo[*d*]imidazole-2-carboxylate (6f) were treated with either ammonia or benzylamine in methanol. Reactions proceeded in the same manner as using pyrazole counterparts and yielded 4-hydroxy-2,3,4,5-tetrahydro-1*H*-[1,4]diazepino[1,2-*a*]indol-1-ones and 4-hydroxy-2,3,4,5-tetrahydro-1*H*-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one 7a–f in fair to excellent (63–98%) yields, with an exception of 7g which was isolated in a mere 19% yield. In comparison, Putey et al. [32] assessed synthesis of 2,3,4,5-tetrahydro[1,4]diazepino[1,2-*a*]indol-1-ones in a 4-step procedure.

To expand the structural diversity and compound library of fused tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones and tetrahydro[1,4]diazepino[1,2-*a*]indol-1-ones, 5-substituted 7-hydroxy-2-phenyl-5,6,7,8-tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones 4i,n,t and 2-benzyl-4-hydroxy-2,3,4,5-tetrahydro-1*H*-[1,4]diazepino[1,2-*a*]indol-1-one 7f were further modified using methyl- and ethyl iodides as *O*-alkylating agents (Scheme 3). Reactions were carried out involving NaH as a base in DMF, where reaction temperature and time were substituent dependent, i.e., compounds bearing benzyl group at 5-position required longer reaction times and higher temperatures. Compounds 8a–f and 9a,b were obtained in 70–92% yields.



Scheme 3. *O*-Alkylation of 5-substituted 7-hydroxy-2-phenyl-5,6,7,8-tetrahydro-4*H*-pyrazolo[1,5-*a*][1,4]diazepin-4-ones 4i,n,t and 2-benzyl-4-hydroxy-2,3,4,5-tetrahydro-1*H*-[1,4]diazepino[1,2-*a*]indol-1-one 7f using methyl and ethyl iodides.

3. Materials and Methods

3.1. General

The reagents and solvents were purchased from commercial suppliers and used without further purification unless otherwise indicated. Reaction progress was monitored by thin-layer chromatography (TLC) on pre-coated ALUGRAM[®]Xtra SIL G/UV₂₅₄ plates (Macherey—Nagel[™], Düren, Germany). The purification of the reaction mixtures was performed using flash chromatography on a glass column, stationary phase—silica gel (high-purity grade 9385, pore size 60 Å, particle size 230–400 mesh, Merck KGaA, Darmstadt, Germany). The ¹H, ¹³C and ¹⁵N-NMR spectra were recorded in chloroform-D (CDCl₃) or dimethyl sulfoxide-*d*₆ (DMSO-*d*₆) at 25 °C on either Jeol ECA-500 (500 MHz—¹H NMR, 126 MHz—¹³C NMR) or Jeol EC2 400R (400 MHz—¹H NMR, 101 MHz—¹³C NMR) spectrometer equipped with a 5 mm Royal probe (JEOL USA, Inc., Peabody, MA, USA), or Bruker Avance III 400 spectrometer (400 MHz—¹H NMR, 101 MHz—¹³C NMR, 40 MHz—¹⁵N NMR) using a 5 mm directly detecting BBO probe (Bruker BioSpin AG, Fallanden, Switzerland). Residual solvent signals were used as internal standards, i.e., for DMSO-*d*₆ $\delta^1_H = 2.50$ and $\delta^{13}_C = 39.52$, for CDCl₃ $\delta^1_H = 7.26$ and $\delta^{13}_C = 77.16$. ¹⁵N chemical shifts were recalculated using a reference of neat external nitromethane standard (coaxial capillary). ¹⁹F NMR spectra (376 MHz) were obtained on a Bruker Avance III 400 instrument; here absolute referencing via δ ratio was used. The full and unambiguous assignments of the ¹H, ¹³C, ¹⁵N-NMR resonances were achieved using a combination of standard NMR spectroscopic techniques. The following abbreviations are used in reporting NMR data: Ph, phenyl; Ox, oxirane. Melting points were determined using the apparatus DigiMelt MPA160 (Stanford Research Systems Inc., Sunnyvale, CA, USA) or Büchi B-540 (Büchi Labortechnik AG, Flawil, Switzerland) and are provided uncorrected. The IR spectra were recorded on a Bruker TENSOR 27 (Bruker Optik GmbH, Ettlingen, Germany) or Nicolet Impact 410 (SpectraLab Scientific Inc., Markham, ON, Canada) FTIR spectrometer using pressured KBr pellets. HRMS spectra were recorded on a micrOTOF-Q III Bruker (Bruker Daltonik GmbH, Bremen, Germany) or Agilent 6230 TOF LC/MS (Agilent Technologies Inc., Santa Clara, CA, United States) spectrometer in electrospray ionization (ESI) mode. ¹H, ¹³C, ¹⁹F, and ¹H,¹⁵N-HMBC NMR spectra, as well as HRMS data of new compounds, are provided in Figures S1–S229 of the Supplementary Materials.

3.2. Synthetic Procedures

3.2.1. General Procedure for Synthesis of Starting 3(5)-Aryl-1*H*-pyrazole-5(3)-carboxylates (**1a–h**) [48,65]

To a 0.5 M solution of sodium ethoxide (1.1 eq) in ethanol, appropriate acetophenone (1 eq) and diethyl oxalate (1 eq) were added, and the resulting mixture was stirred at room temperature for 16 h in an inert atmosphere. Upon completion, the reaction mixture was quenched with 1 M HCl solution until neutral pH and extracted with ethyl acetate. Organic layer was washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 15/1, *v/v*). Obtained ketoester (1 eq) was dissolved in a mixture of ethanol and acetic acid (7/3, *v/v*, 0.2 M), 55% aqueous hydrazine hydrate solution (1.1 eq) was added, and the reaction mixture was stirred at room temperature for 16 h. Subsequently, solvents were evaporated, and residue was dissolved in ethyl acetate and washed with 10% aqueous NaHCO₃ solution. Organic layer was washed again with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (*n*-hexane/ethyl acetate/methanol gradient from 8/1/0.1 to 1/1/0.1, *v/v/v*) to give corresponding pyrazoles **1a–h** in good yields (75–87%).

3.2.2. Synthesis of Ethyl 1-(oxiran-2-ylmethyl)-1H-pyrazole-3(5)-carboxylates (**2a–h** and **3a,f–h**)

Appropriate pyrazole **1a–h** (1 eq) was dissolved in dry dimethyl formamide (0.4 M) and NaH (1.5 eq; 60% dispersion in mineral oil) was added followed by 2-(chloromethyl)oxirane (1.5 eq). The reaction mixture was stirred at 40 °C for 1–5 h. Upon completion, the reaction mixture was concentrated to approximately 1/3 volume, diluted with ethyl acetate, and washed with brine. Organic layer was separated, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

Ethyl 1-(oxiran-2-ylmethyl)-3-phenyl-1H-pyrazole-5-carboxylate **2a**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 10/1 to 8/1, *v/v*). White solid, mp 53–54 °C, 60% (3.13 g). *R_f* = 0.72 (*n*-hexane/ethyl acetate 7/3, *v/v*). IR (KBr) ν_{\max} , cm⁻¹: 2981, 1721 (C=O), 1261, 1086, 1073, 764, 758, 693, 436. ¹H NMR (400 MHz, CDCl₃) δ_{H} ppm: 1.41 (t, *J* = 7.1 Hz, 3H, CH₃), 2.58–2.63 (m, 1H, Ox CH_aH_b), 2.81 (t, *J* = 4.4 Hz, 1H, CH_aH_b), 3.40–3.47 (m, Ox 1H, CH), 4.38 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 4.83 (qd, *J* = 14.2, 4.6 Hz, 2H, NCH₂), 7.15 (s, 1H, 4-H), 7.29–7.37 (m, 1H, Ph 4-H), 7.38–7.44 (m, 2H, Ph 3,5-H), 7.78–7.84 (m, 2H, Ph 2,6-H). ¹³C NMR (101 MHz, CDCl₃) δ_{C} ppm: 14.4 (CH₃), 45.8 (Ox CH₂), 50.7 (Ox CH), 53.0 (NCH₂), 61.4 (CH₂CH₃), 108.4 (C-4), 125.8 (Ph C-2,6), 128.3 (Ph C-4), 128.8 (Ph C-3,5), 132.5 (Ph C-1), 134.3 (C-5), 150.7 (C-3), 159.9 (C=O). ¹⁵N NMR (40 MHz, CDCl₃) δ_{N} ppm: –175.6 (N-1), –66.2 (N-2). HRMS (ESI) for C₁₅H₁₆N₂NaO₃ ([M+Na]⁺): calcd *m/z* 295.1053, found *m/z* 295.1053.

Ethyl 3-(4-fluorophenyl)-1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate **2b**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 8/1, *v/v*). White solid, mp 98–99 °C, 59% (2.04 g). *R_f* = 0.56 (*n*-hexane/ethyl acetate 7/3, *v/v*). IR (KBr) ν_{\max} , cm⁻¹: 3140, 3061, 2979, 1730 (C=O), 1445, 1263, 1214, 1086, 849, 761. ¹H NMR (400 MHz, DMSO-*d*₆) δ_{H} ppm: 1.33 (t, *J* = 7.1 Hz, 3H, CH₃), 2.48–2.51 (m, 1H, Ox CH_aH_b), 2.72 (t, *J* = 4.5 Hz, 1H, Ox CH_aH_b), 3.36–3.42 (m, 1H, Ox CH), 4.33 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 4.60 (dd, *J* = 14.5, 5.5 Hz, 1H, NCH_a), 4.85 (dd, *J* = 14.5, 3.6 Hz, 1H, NCH_b), 7.21–7.29 (m, 2H, Ph 3,5-H), 7.38 (s, 1H, 4-H), 7.86–7.95 (m, 2H, Ph 2,6-H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_{C} ppm: 14.0 (CH₃), 44.8 (Ox CH₂), 50.2 (Ox CH), 52.8 (NCH₂), 61.1 (CH₂CH₃), 108.0 (C-4), 115.65 (d, ²*J*_{CF} = 21.6 Hz, Ph C-3,5), 127.35 (d, ³*J*_{CF} = 8.3 Hz, Ph C-2,6), 128.54 (d, ⁴*J*_{CF} = 3.0 Hz, Ph C-1), 134.1 (C-5), 148.6 (C-3), 159.0 (C=O), 162.07 (d, *J*_{CF} = 244.8 Hz, Ph C-4). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_{N} ppm: –173.3 (N-1), –65.1 (N-2). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ_{F} ppm: –113.8 (Ph 6-F). HRMS (ESI) for C₁₅H₁₅FN₂NaO₃ ([M+Na]⁺): calcd *m/z* 313.0959, found *m/z* 313.0959.

Ethyl 3-(4-chlorophenyl)-1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate **2c**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 8/1 to 7/1, *v/v*). Pale yellow solid, mp 110–111 °C, 53% (551 mg). *R_f* = 0.57 (*n*-hexane/ethyl acetate 7/3, *v/v*). IR (KBr) ν_{\max} , cm⁻¹: 3127, 2982, 2960, 1715 (C=O), 1460, 1266, 1123, 1088, 835, 766. ¹H NMR (400 MHz, DMSO-*d*₆) δ_{H} ppm: 1.34 (t, *J* = 7.1 Hz, 3H, CH₃), 2.51–2.53 (m, 1H, Ox CH_aCH_b), 2.79 (t, *J* = 4.5 Hz, 1H, Ox CH_aH_b), 3.37–3.43 (m, 1H, Ox CH), 4.34 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 4.61 (dd, *J* = 14.5, 5.6 Hz, 1H, NCH_a), 4.86 (dd, *J* = 14.4, 3.6 Hz, 1H, NCH_b), 7.42 (s, 1H, 4-H), 7.45–7.51 (m, 2H, Ph 3,5-H), 7.86–7.93 (m, 2H, Ph 2,6-H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_{C} ppm: 14.0 (CH₃), 44.8 (Ox CH₂), 50.1 (Ox CH), 52.9 (NCH₂), 61.1 (CH₂CH₃), 108.3 (C-4), 127.0 (Ph C-2,6), 128.8 (Ph C-3,5), 130.8 (Ph C-1), 132.7 (Ph C-4), 134.2 (C-5), 148.3 (C-3), 159.0 (C=O). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_{N} ppm: –172.3 (N-1), –65.2 (N-2). HRMS (ESI) for C₁₅H₁₅ClN₂NaO₃ ([M+Na]⁺): calcd *m/z* 329.0663, found *m/z* 329.0663.

Ethyl 3-(4-bromophenyl)-1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate 2d

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 10/1 to 8/1, *v/v*). White solid, mp 120–121 °C, 58% (1.88 g). $R_f = 0.60$ (*n*-hexane/ethyl acetate 7/3, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 3127, 2979, 1716 (C=O), 1459, 1436, 1267, 1123, 1092, 832, 766. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 1.33 (t, $J = 7.1$ Hz, 3H, CH₃), 2.48–2.52 (m, 1H, Ox CH_aH_b), 2.78 (t, $J = 4.5$ Hz, 1H, Ox CH_aH_b), 3.37–3.42 (m, 1H, Ox CH), 4.33 (q, $J = 7.1$ Hz, 2H, CH₂CH₃), 4.60 (dd, $J = 14.5, 5.6$ Hz, 1H, NCH_a), 4.86 (dd, $J = 14.5, 3.6$ Hz, 1H, NCH_b), 7.43 (s, 1H, 4-H), 7.58–7.64 (m, 2H, Ph 3,5-H), 7.79–7.86 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 14.0 (CH₃), 44.8 (Ox CH₂), 50.1 (Ox CH), 52.9 (NCH₂), 61.1 (CH₂CH₃), 108.3 (C-4), 121.3 (Ph C-4), 127.3 (Ph C-2,6), 131.2 (Ph C-3,5), 131.7 (Ph C-1), 134.2 (C-5), 148.4 (C-3), 159.0 (C=O). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –172.3 (N-1), –64.8 (N-2). HRMS (ESI) for C₁₅H₁₅BrN₂NaO₃ ([M+Na]⁺): calcd m/z 373.0158, found m/z 373.0158 and 375.0136.

Ethyl 3-(4-methoxyphenyl)-1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate 2e

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 8/1, *v/v*). White solid, mp 75–76 °C, 61% (1.9 g). $R_f = 0.49$ (*n*-hexane/ethyl acetate 7/2 *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 3139, 2975, 2938, 2836, 1726 (C=O), 1447, 1086, 1029, 846, 758. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 1.33 (t, $J = 7.1$ Hz, 3H, CH₃), 2.47–2.50 (m, 1H, Ox CH_aCH_b), 2.78 (t, $J = 4.5$ Hz, 1H, Ox CH_aH_b), 3.35–3.42 (m, 1H, Ox CH), 3.79 (s, 3H, OCH₃), 4.33 (q, $J = 7.1$ Hz, 2H, CH₂CH₃), 4.59 (dd, $J = 14.5, 5.5$ Hz, 1H, NCH_a), 4.84 (dd, $J = 14.4, 3.5$ Hz, 1H, NCH_b), 6.93–7.02 (m, 2H, Ph 3,5-H), 7.30 (s, 1H, 4-H), 7.75–7.83 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 14.1 (CH₃), 44.8 (Ox CH₂), 50.2 (Ox CH), 52.7 (NCH₂), 55.2 (OCH₃), 61.0 (CH₂CH₃), 107.5 (C-4), 114.2 (Ph C-3,5), 124.6 (Ph C-1), 126.6 (Ph C-2,6), 133.9 (C-5), 149.4 (C-3), 159.1 (C=O), 159.3 (Ph C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –174.5 (N-1) –67.0 (N-2). HRMS (ESI) for C₁₆H₁₈N₂NaO₄ ([M+Na]⁺): calcd m/z 325.1159, found m/z 325.1159.

Ethyl 1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate 2f

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 4/1, *v/v*). Colorless liquid, 21% (30 mg). $R_f = 0.57$ (*n*-hexane/ethyl acetate 2/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2985, 1722 (C=O), 1518, 1312, 1254, 1121, 1105, 1039, 765. ^1H NMR (400 MHz, CDCl₃) δ_{H} ppm: 1.39 (t, $J = 7.1$ Hz, 3H, CH₃), 2.54–2.56 (m, 1H, Ox CH_aH_b), 2.80 (t, $J = 4.4$ Hz, 1H, Ox CH_aH_b), 3.37–3.40 (m, 1H, Ox CH), 4.36 (q, $J = 7.1$ Hz, 2H, CH₂CH₃), 4.73 (dd, $J = 14.2, 5.2$ Hz, 1H, NCH_aH_b), 4.86 (dd, $J = 14.2, 4.2$ Hz, 1H, NCH_aH_b), 6.86 (d, $J = 1.5$ Hz, 1H, 4-H), 7.53 (d, $J = 1.4$ Hz, 1H, 3-H). ^{13}C NMR (101 MHz, CDCl₃) δ_{C} ppm: 14.3 (CH₃), 45.8 (Ox CH₂), 50.7 (Ox CH), 53.0 (NCH₂), 61.3 (CH₂CH₃), 111.6 (C-4), 133.0 (C-5), 138.8 (C-3), 159.9 (COO). ^{15}N NMR (40 MHz, CDCl₃) δ_{N} ppm: –173.5 (N-1), –60.2 (N-2). HRMS (ESI) for C₉H₁₃N₂O₃ ([M+H]⁺): calcd m/z 197.0921, found m/z 197.0916.

Ethyl 4-methyl-1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate 2g

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 4/1, *v/v*). Colorless liquid, 26% (36 mg). $R_f = 0.47$ (*n*-hexane/ethyl acetate 2/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2983, 1716 (C=O), 1449, 1277, 1113, 1042. ^1H NMR (400 MHz, CDCl₃) δ_{H} ppm: 1.40 (t, $J = 7.1$ Hz, 3H, CH₂CH₃), 2.26 (s, 3H, 4-CH₃), 2.52–2.54 (m, 1H, Ox CH_aH_b), 2.78 (t, $J = 4.4$ Hz, 1H, Ox CH_aH_b), 3.34–3.37 (m, 1H, Ox CH), 4.38 (q, $J = 7.1$ Hz, 2H, CH₂CH₃), 4.68 (dd, $J = 14.3, 5.1$ Hz, 1H, NCH_aH_b), 4.80 (dd, $J = 14.3, 4.1$ Hz, 1H, NCH_aH_b), 7.36 (s, 1H, 3-H). ^{13}C NMR (101 MHz, CDCl₃) δ_{C} ppm: 10.9 (4-CH₃), 14.3 (CH₂CH₃), 45.7 (Ox CH₂), 50.8 (Ox CH), 53.5 (NCH₂), 61.0 (CH₂CH₃), 123.1 (C-4), 130.1 (C-5), 140.2 (C-3), 160.7 (COO). ^{15}N NMR (40 MHz, CDCl₃) δ_{N} ppm: –174.6 (N-1), –63.9 (N-2). HRMS (ESI) for C₁₀H₁₅N₂O₃ ([M+H]⁺): calcd m/z 211.1077, found m/z 211.1067.

Ethyl 3-methyl-1-(oxiran-2-ylmethyl)-1H-pyrazole-5-carboxylate 2h

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 4/1, *v/v*). Colorless liquid, 24% (32 mg). $R_f = 0.42$ (*n*-hexane/ethyl acetate 2/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2962, 2909, 1722 (C=O), 1461, 1262, 1085, 767. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.37 (t, $J = 7.1$ Hz, 3H, CH_2CH_3), 2.28 (s, 3H, 3- CH_3), 2.55–2.57 (m, 1H, Ox CH_aH_b), 2.79 (t, $J = 4.4$ Hz, 1H, Ox CH_aH_b), 3.34–3.38 (m, 1H, Ox CH), 4.33 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.63 (dd, $J = 14.3, 5.2$ Hz, 1H, NCH_aH_b), 4.78 (dd, $J = 14.3, 4.1$ Hz, 1H, NCH_aH_b), 6.64 (s, 1H, 4-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 13.5 (3- CH_3), 14.4 (CH_2CH_3), 45.8 (Ox CH_2), 50.8 (Ox CH), 52.7 (NCH_2), 61.2 (CH_2CH_3), 111.0 (C-4), 133.4 (C-5), 148.0 (C-3), 160.0 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –178.6 (N-1), –64.1 (N-2). HRMS (ESI) for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 211.1077, found m/z 211.1075.

Ethyl 1-(oxiran-2-ylmethyl)-5-phenyl-1H-pyrazole-3-carboxylate 3a

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 8/1 to 1/1, *v/v*). Colorless resin, 56% (20 mg). $R_f = 0.37$ (*n*-hexane/ethyl acetate 1/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2986, 1729 (C=O), 1214, 765, 701. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.41 (t, $J = 7.1$ Hz, 3H, CH_3), 2.49–2.53 (m, 1H, Ox CH_aH_b), 2.81 (t, $J = 4.3$ Hz, 1H, Ox CH_aH_b), 3.40–3.45 (m, 1H, Ox CH), 4.26–4.47 (m, 4H, CH_2CH_3 , NCH_2), 6.84 (s, 1H, 4-H), 7.42–7.51 (m, 5H, Ph 2,3,4,5,6-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 14.6 (CH_3), 46.0 (Ox CH_2), 50.7 (Ox CH), 51.6 (NCH_2), 61.2 (CH_2CH_3), 109.2 (C-4), 129.0 (Ph C-1,2,6), 129.4 (Ph C-4), 129.5 (Ph C-3,5), 143.7 (C-3), 146.2 (C-5), 162.5 (C=O). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –174.4 (N-1), –70.0 (N-2). HRMS (ESI) for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 295.1053, found m/z 295.1051.

Ethyl 1-(oxiran-2-ylmethyl)-1H-pyrazole-3-carboxylate 3f

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 2/1, *v/v*). Colorless liquid, 28% (39 mg). $R_f = 0.49$ (*n*-hexane/ethyl acetate 1/2, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2986, 1721 (C=O), 1375, 1237, 1173, 1154, 1027, 765. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.40 (t, $J = 7.1$, 3H, CH_3), 2.49–2.51 (m, 1H, Ox CH_aH_b), 2.87 (t, $J = 4.2$ Hz, 1H, Ox CH_aH_b), 3.36–3.38 (m, 1H, Ox CH), 4.21 (dd, $J = 14.7, 6.0$ Hz, 1H, NCH_aH_b), 4.41 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.62 (dd, $J = 14.7, 2.6$ Hz, 1H, NCH_aH_b), 6.84 (d, $J = 2.1$ Hz, 1H, 4-H), 7.53 (d, $J = 2.1$ Hz, 1H, 5-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 14.5 (CH_3), 45.5 (Ox CH_2), 50.4 (Ox CH), 54.6 (NCH_2), 61.2 (CH_2CH_3), 109.5 (C-4), 131.7 (C-5), 144.2 (C-3), 162.4 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –171.8 (N-1), –68.9 (N-2). HRMS (ESI) for $\text{C}_9\text{H}_{13}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 197.0921, found m/z 197.0915.

Ethyl 4-methyl-1-(oxiran-2-ylmethyl)-1H-pyrazole-3-carboxylate 3g

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 2/1, *v/v*). Colorless liquid, 35% (48 mg). $R_f = 0.47$ (*n*-hexane/ethyl acetate 1/2, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2983, 2932, 1716 (C=O), 1448, 1367, 1254, 1108. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.41 (t, $J = 7.1$ Hz, 3H, CH_2CH_3), 2.29 (s, 3H, 4- CH_3), 2.49–2.51 (m, 1H, Ox CH_aH_b), 2.86 (t, $J = 4.2$ Hz, 1H, Ox CH_aH_b), 3.33–3.35 (m, 1H, Ox CH), 4.13 (dd, $J = 14.7, 6.0$ Hz, 1H, NCH_aH_b), 4.41 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.55 (dd, $J = 14.7, 2.5$ Hz, 1H, NCH_aH_b), 7.33 (s, 1H, 5-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 9.9 (4- CH_3), 14.5 (CH_2CH_3), 45.4 (Ox CH_2), 50.5 (Ox CH), 54.5 (NCH_2), 60.8 (CH_2CH_3), 121.5 (C-4), 131.0 (C-5), 141.4 (C-3), 163.0 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –175.7 (N-1), –69.2 (N-2). HRMS (ESI) for $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 211.1077, found m/z 211.1072.

Ethyl 5-methyl-1-(oxiran-2-ylmethyl)-1H-pyrazole-3-carboxylate 3h

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 2/1, *v/v*). White solid, mp 31–33 °C, 29% (40 mg). $R_f = 0.47$ (*n*-hexane/ethyl acetate 1/2, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2985, 1721 (C=O), 1446, 1386, 1228, 1032, 780. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.39 (t, $J = 7.1$ Hz, 3H, CH_2CH_3), 2.34 (s, 3H, 5- CH_3),

2.47–2.49 (m, 1H, Ox CH_aH_b), 2.82 (t, $J = 4.3$ Hz, 1H, Ox CH_aH_b), 3.33–3.37 (m, 1H, Ox CH), 4.21 (dd, $J = 15.0, 5.2$ Hz, 1H, NCH_aH_b), 4.39 (q, $J = 7.1$ Hz, 2H, CH₂CH₃) 4.53 (dd, $J = 15.0, 2.4$ Hz, 1H, NCH_aH_b), 6.57 (s, 1H, 4-H). ¹³C NMR (101 MHz, CDCl₃) δ_C ppm: 11.4 (5-CH₃), 14.5 (CH₂CH₃), 45.3 (Ox CH₂), 50.9 (Ox CH), 51.4 (NCH₂), 61.0 (CH₂CH₃), 108.6 (C-4), 141.3 (C-5), 143.1 (C-3), 162.6 (COO). ¹⁵N NMR (40 MHz, CDCl₃) δ_N ppm: −173.3 (N-1), −70.8 (N-2). HRMS (ESI) for C₁₀H₁₅N₂O₃ ([M+H]⁺): calcd m/z 211.1077, found m/z 211.1070.

3.2.3. Synthesis of 7-Hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-ones (4a–x)

Procedure a. Carboxylate **2a–h** (1 eq) was dissolved in 2M ammonia (30 eq) solution in methanol, sealed in a pressure tube and stirred at 70 °C for 5–18 h. After completion, excess of ammonia in methanol was evaporated under reduced pressure. The residue was purified by column chromatography.

Procedure b. To a solution of carboxylate **2a–e** (1 eq) in methanol (5 M), appropriate primary amine (3 eq) was added, the reaction mixture was sealed in a pressure tube and was stirred at 70 °C for 7 h. After completion, the reaction mixture was poured into water and extracted with ethyl acetate. Combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

7-Hydroxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one **4a**

Purified by column chromatography on silica gel (gradient from *n*-hexane/ethyl acetate/methanol gradient from 1/9/0 to 1/15/0.5, *v/v*). White solid, decomp. 246 °C, procedure a −34% (27 mg). $R_f = 0.40$ (dichloromethane/methanol 100/5, *v/v*). IR (KBr) ν_{\max} , cm^{−1}: 3270, 3196, 3074, 2925, 1681 (C=O), 1460, 1440, 771, 752, 685. ¹H NMR (400 MHz, DMSO-*d*₆) δ_H ppm: 2.85–2.96 (m, 1H, 6-H_a), 3.21–3.30 (m, 1H, 6-H_b), 4.20–4.33 (m, 2H, 7-H, 8-H_a), 4.54 (dd, $J = 13.8, 4.8$ Hz, 1H, 8-H_b), 5.49 (d, $J = 3.8$ Hz, 1H, OH), 7.16 (s, 1H, 3-H), 7.28–7.35 (m, 1H, Ph 4-H), 7.36–7.45 (m, 2H, Ph 3,5-H), 7.80–7.88 (m, 2H, Ph 2,6-H), 8.24–8.31 (m, 1H, NH). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_C ppm: 45.5 (C-6), 56.2 (C-8), 69.4 (C-7), 105.8 (C-3), 125.1 (Ph C-2,6), 127.8 (Ph C-4), 128.7 (Ph C-3,5), 132.5 (Ph C-1), 139.4 (C-3a), 149.0 (C-2), 163.2 (C-4). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_N ppm: −270.4 (N-5), −175.4 (N-9), −73.6 (N-1). HRMS (ESI) for C₁₃H₁₃N₃NaO₂ ([M+Na]⁺): calcd m/z 266.0900, found m/z 266.0900.

2-(4-Fluorophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one **4b**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate/methanol gradient from 1/9/0 to 1/15/0.5, *v/v*). Pale yellow solid, decomp. 216 °C, procedure a −56% (86 mg). $R_f = 0.38$ (dichloromethane/methanol 100/5, *v/v*). IR (KBr) ν_{\max} , cm^{−1}: 3305, 3206, 3071, 2947, 2923, 1681, 1457, 1442, 841, 809. ¹H NMR (400 MHz, DMSO-*d*₆) δ_H ppm: 3.74 (dt, $J = 12.2, 5.8$ Hz, 1H, 6-H_a), 4.09 (dt, $J = 14.5, 5.4$ Hz, 1H, 6-H_b), 5.02–5.15 (m, 2H, 7-H, 8-H_a), 5.36 (dd, $J = 13.9, 5.0$ Hz, 1H, 8-H_b), 8.00 (s, 1H, 3-H), 8.04–8.11 (m, 2H, Ph 3,5-H), 8.67–8.75 (m, 2H, Ph 2,6-H), 9.12–9.18 (m, 1H, NH). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_C ppm: 45.5 (C-6), 56.2 (C-8), 69.3 (C-7), 105.8 (C-3), 115.59 (d, ² $J_{CF} = 21.5$ Hz, Ph C-3,5), 127.12 (d, ³ $J_{CF} = 8.2$ Hz, Ph C-2,6), 129.10 (d, ⁴ $J_{CF} = 3.0$ Hz, Ph C-1), 139.6 (C-3a), 148.2 (C-2), 161.83 (d, $J_{CF} = 244.3$ Hz, Ph C-4), 163.1 (C-4). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_N ppm: −270.5 (N-5), −175.3 (N-9), −73.8 (N-1). ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ_F ppm: −114.4 (Ph 6-F). HRMS (ESI) for C₁₃H₁₂FN₃NaO₂ ([M+Na]⁺): calcd m/z 284.0806, found m/z 284.0806.

2-(4-Chlorophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one **4c**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate/methanol gradient from 1/9/0 to 1/20/0.5, *v/v*). White solid, decomp. 249 °C, procedure a −48% (59 mg). $R_f = 0.38$ (dichloromethane/methanol 100/5, *v/v*). IR (KBr) ν_{\max} , cm^{−1}: 3297,

3210, 3080, 2917, 1683 (C=O), 1451, 1435, 1089, 834, 809. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 2.86–2.95 (m, 1H, 6- H_a), 3.21–3.30 (m, 1H, 6- H_b), 4.19–4.31 (m, 2H, 7-H, 8- H_a), 4.54 (dd, $J = 13.9, 4.9$ Hz, 1H, 8- H_b), 5.53 (br s, 1H, OH), 7.20 (s, 1H, 3-H), 7.43–7.50 (m, 2H, Ph 3,5-H), 7.82–7.91 (m, 2H, Ph 2,6-H), 8.28–8.33 (m, 1H, NH). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 45.5 (C-6), 56.3 (C-8), 69.3 (C-7), 106.0 (C-3), 126.8 (Ph C-2,6), 128.8 (Ph C-3,5), 131.4 (Ph C-1), 132.3 (Ph C-4), 139.6 (C-3a), 147.9 (C-2), 163.0 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –270.4 (N-5), –174.0 (N-9), –69.7 (N-1). HRMS (ESI) for $\text{C}_{13}\text{H}_{12}\text{ClN}_3\text{NaO}_2$ ($[\text{M}+\text{Na}]^+$): calcd m/z 300.0510, found m/z 300.0510.

2-(4-Bromophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4d**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate/methanol gradient from 1/9/0 to 1/12/0.5, *v/v*). White solid, decomp. 230 °C, procedure a –51% (50 mg). $R_f = 0.40$ (dichloromethane/methanol 100/5, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3292, 3214, 3079, 1680 (C=O), 1455 and 1434 (doublet), 1071, 991, 922, 816 and 807 (doublet). ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 2.90 (dt, $J = 12.2, 5.8$ Hz, 1H, 6- H_a), 3.26 (dt, $J = 14.4, 5.3$ Hz, 1H, 6- H_b), 4.19–4.33 (m, 2H, 7-H, 8- H_a), 4.54 (dd, $J = 13.9, 4.9$ Hz, 1H, 8- H_b), 5.49 (d, $J = 41$ Hz, 1H, OH), 7.20 (s, 1H, 3-H), 7.57–7.64 (m, 2H, Ph 3,5-H), 7.76–7.84 (m, 2H, Ph 2,6-H), 8.29 (t, $J = 5.1$ Hz, 1H, NH). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 45.5 (C-6), 56.3 (C-8), 69.3 (C-7), 106.0 (C-3), 120.8 (Ph C-4), 127.1 (Ph C-2,6), 131.7 (Ph C-3,5), 131.8 (Ph C-1), 139.6 (C-3a), 148.0 (C-2), 163.0 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –173.4 (N-9), –72.7 (N-1). HRMS (ESI) for $\text{C}_{13}\text{H}_{12}\text{BrN}_3\text{NaO}_2$ ($[\text{M}+\text{Na}]^+$): calcd m/z 344.0005, found m/z 344.0005 and 345.9983.

7-Hydroxy-2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4e**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate/methanol gradient from 1/9/0 to 1/10/0.5, *v/v*). White solid, decomp. 239 °C, procedure a –40% (38 mg). $R_f = 0.41$ (dichloromethane/methanol 100/5, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3200, 3078, 2928, 1681 (C=O), 1463, 1447, 1251, 1176, 1027, 821. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 2.91 (dt, $J = 11.9, 5.7$ Hz, 1H, 6- H_a), 3.25 (dt, $J = 14.6, 5.4$ Hz, 1H, 6- H_b), 3.78 (s, 3H, OCH_3), 4.18–4.32 (m, 2H, 7-H, 8- H_a), 4.51 (dd, $J = 14.1, 5.1$ Hz, 1H, 8- H_b), 5.48 (d, $J = 4.2$ Hz, 1H, OH), 6.94–7.00 (m, 2H, Ph 3,5-H), 7.07 (s, 1H, 3-H), 7.73–7.79 (m, 2H, Ph 2,6-H), 8.22–8.27 (m, 1H, NH). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 45.6 (C-6), 55.1 (CH_3), 56.1 (C-8), 69.4 (C-7), 105.2 (C-3), 114.1 (Ph C-3,5), 125.2 (Ph C-1), 126.4 (Ph C-2,6), 139.3 (C-3a), 149.0 (C-3), 156.0 (Ph C-4), 163.2 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –270.1 (N-5), –176.5 (N-9), –74.9 (N-1). HRMS (ESI) for $\text{C}_{14}\text{H}_{15}\text{N}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 296.1006, found m/z 296.1006.

7-Hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4f**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, *v/v*). White solid, decomp. 195 °C, procedure a –89% (76 mg). $R_f = 0.41$ (dichloromethane/methanol 9/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3210, 3127, 3081, 2933, 1685 (C=O), 1387, 1351, 1182, 825. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 2.81–2.87 (m, 1H, 6- H_a), 3.16–3.22 (m, 1H, 6- H_b), 4.18 (dd, $J = 14.0, 4.3$ Hz, 1H, 8- H_a), 4.21–4.27 (m, 1H, 7-H), 4.48 (dd, $J = 14.0, 5.1$ Hz, 1H, 8- H_b), 5.44 (d, $J = 4.0$ Hz, 1H, OH), 6.66 (d, $J = 0.7$ Hz, 1H, 3-H), 7.47 (d, $J = 0.6$ Hz, 1H, 2-H), 8.22 (s, 1H, NH). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 45.6 (C-6), 55.9 (C-8), 69.4 (C-7), 108.8 (C-3), 137.79 (C-3a), 137.83 (C-2), 163.4 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –271.1 (N-5), –173.3 (N-9), –66.0 (N-1). HRMS (ESI) for $\text{C}_7\text{H}_{10}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 168.0768, found m/z 168.0763.

7-Hydroxy-3-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4g**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, *v/v*). White solid, decomp. 213 °C, procedure a –77% (67 mg). $R_f = 0.45$ (dichloromethane/methanol 9/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3301, 3203, 3078, 2932, 1678 (C=O), 1382, 1320,

1247, 1099, 922. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 2.10 (s, 3H, CH_3), 2.77–2.84 (m, 1H, 6- H_a), 3.12–3.19 (m, 1H, 6- H_b), 4.09 (dd, $J = 14.2, 4.2$ Hz, 1H, 8- H_a), 4.17–4.23 (m, 1H, 7-H), 4.40 (dd, $J = 14.1, 5.4$ Hz, 1H, 8- H_b), 5.39 (d, $J = 4.1$ Hz, 1H, OH), 7.29 (s, 1H, 2-H), 8.14 (s, 1H, NH). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 8.7 (CH_3), 45.5 (C-6), 55.7 (C-8), 69.7 (C-7), 119.4 (C-3), 133.8 (C-3a), 138.4 (C-2), 164.0 (COO). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –270.3 (N-5), –176.2 (N-9), –69.1 (N-1). HRMS (ESI) for $\text{C}_8\text{H}_{12}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 182.0924, found m/z 182.0923.

7-Hydroxy-2-methyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4h**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, v/v). White solid, decomp. 232 °C, procedure a –90% (78 mg). $R_f = 0.44$ (dichloromethane/methanol 9/1, v/v). IR (KBr) ν_{max} , cm^{-1} : 3254, 3144, 2936, 1689 (C=O), 1635, 1464, 1453, 1135, 1054, 758. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 2.16 (s, 1H, CH_3), 2.82–2.89 (m, 1H, 6- H_a), 3.15–3.21 (m, 1H, 6- H_b), 4.08 (dd, $J = 14.2, 4.4$ Hz, 1H, 8- H_a), 4.17–4.24 (m, 1H, 7-H), 4.38 (dd, $J = 14.2, 5.4$ Hz, 1H, 8- H_b), 5.40 (d, $J = 4.1$ Hz, 1H, OH), 6.43 (s, 1H, 3-H), 8.15 (s, 1H, NH). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 13.0 (CH_3), 45.6 (C-6), 55.5 (C-8), 69.5 (C-7), 108.1 (C-3), 138.4 (C-3a), 146.1 (C-2), 163.4 (COO). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –271.6 (N-5), –178.8 (N-9), –68.9 (N-1). HRMS (ESI) for $\text{C}_8\text{H}_{12}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 182.0924, found m/z 182.0923.

7-Hydroxy-5-(2-methoxyethyl)-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4i**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 1/9, v/v). White solid, mp 134–135 °C, procedure b –81% (99 mg). $R_f = 0.40$ (ethyl acetate). IR (KBr) ν_{max} , cm^{-1} : 3274, 3135, 2932, 1651 (C=O), 1435, 1296, 1177, 1113, 764, 691. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 3.15 (dd, $J = 15.0, 7.5$ Hz, 1H, 5- CH_a), 3.29 (s, 3H, CH_3), 3.41–3.56 (m, 4H, 5- CH_b , CH_2O , 6- H_a), 3.89 (dt, $J = 13.5, 5.2$ Hz, 1H, 6- H_b), 4.24 (dd, $J = 14.1, 3.2$ Hz, 1H, 8- H_a), 4.35–4.42 (m, 1H, 7-H), 4.47 (dd, $J = 14.1, 5.1$ Hz, 1H, 8- H_b), 5.52 (d, $J = 4.3$ Hz, 1H, OH), 7.17 (s, 1H, 3-H), 7.28–7.34 (m, 1H, Ph 4-H), 7.37–7.45 (m, 2H, Ph 3,5-H), 7.81–7.86 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 46.8 (C-6), 52.8 (5- CH_2), 55.9 (C-8), 58.0 (CH_3), 69.5 (C-7), 69.9 (CH_2O), 105.4 (C-3), 125.1 (Ph C-2,6), 127.8 (Ph C-4), 128.7 (Ph C-3,5), 132.5 (Ph C-1), 139.3 (C-3a), 149.0 (C-2), 161.6 (C-4). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –264.8 (N-5), –175.6 (N-9), –73.7 (N-1). HRMS (ESI) for $\text{C}_{16}\text{H}_{19}\text{N}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 324.1319, found m/z 324.1319.

2-(4-Fluorophenyl)-7-hydroxy-5-(2-methoxyethyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4j**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 1/5, v/v). White solid, mp 133–134 °C, procedure b –84% (285 mg). $R_f = 0.46$ (ethyl acetate). IR (KBr) ν_{max} , cm^{-1} : 3299, 2941, 2903, 2819, 1620, 1471, 1215, 1113, 827, 806. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 3.14 (dd, $J = 15.0, 7.5$ Hz, 1H, 6- H_a), 3.28 (s, 3H, CH_3), 3.39–3.57 (m, 4H, 5- CH_a , 6- H_b , CH_2O), 3.89 (dt, $J = 10.6, 5.0$ Hz, 1H, 5- CH_b), 4.23 (dd, $J = 14.1, 2.6$ Hz, 1H, 8- H_a), 4.34–4.50 (m, 2H, 7-H, 8- H_b), 5.52 (d, $J = 3.9$ Hz, 1H, OH), 7.17 (s, 1H, 3-H), 7.20–7.28 (m, 2H, Ph 3,5-H), 7.84–7.92 (m, 5.9 Hz, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 46.8 (5- CH_2), 52.8 (C-6), 55.9 (C-8), 58.0 (CH_3), 69.5 (C-7), 69.9 (CH_2O), 105.4 (C-3), 115.59 (d, $^2J_{\text{CF}} = 21.5$ Hz, Ph C-3,5), 127.09 (d, $^3J_{\text{CF}} = 8.2$ Hz, Ph C-2,6), 129.1 (d, $^4J_{\text{CF}} = 3.0$ Hz, Ph C-1), 139.4 (C-3a), 148.1 (C-2), 161.5 (C-4), 161.82 (d, $J_{\text{CF}} = 244.3$ Hz, Ph C-4). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –264.6 (N-5), –175.6 (N-9), –75.2 (N-1). ^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) δ_{F} ppm: –114.4 (1F, m, Ph 6-F). HRMS (ESI) for $\text{C}_{16}\text{H}_{18}\text{FN}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 342.1224, found m/z 342.1224.

2-(4-Chlorophenyl)-7-hydroxy-5-(2-methoxyethyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4k

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 1/9, *v/v*). Pale pink solid, mp 148–149 °C, procedure b –98% (221 mg). $R_f = 0.41$ (ethyl acetate). IR (KBr) ν_{\max} , cm^{-1} : 3300, 2941, 2877, 1623 (C=O), 1469, 1400, 1111, 1068, 826, 756. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.14 (dd, $J = 14.9, 7.4$ Hz, 1H, 6- H_a), 3.29 (s, 3H, CH_3), 3.40–3.58 (m, 4H, 5- CH_a , 6- H_b , CH_2O), 3.84–3.94 (m, 1H, 5- CH_b), 4.24 (dd, $J = 14.1, 2.5$ Hz, 1H, 8- H_a), 4.35–4.51 (m, 2H, 7-H, 8- H_b), 5.53 (d, $J = 3.8$ Hz, 1H, OH), 7.21 (s, 1H, 3-H), 7.37–7.54 (m, 2H, Ph 3,5-H), 7.77–7.95 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 46.8 (5- CH_2), 52.8 (C-6), 56.0 (C-8), 58.0 (CH_3), 69.5 (C-7), 69.9 (CH_2O), 105.7 (C-3), 126.8 (Ph C-2,6), 128.8 (Ph C-3,5), 131.4 (Ph C-1), 132.3 (Ph C-4), 139.5 (C-3a), 147.9 (C-2), 161.4 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –264.3 (N-5), –174.7 (N-9), –74.3 (N-1). HRMS (ESI) for $\text{C}_{16}\text{H}_{18}\text{ClN}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 358.0929, found m/z 358.0929.

2-(4-Bromophenyl)-7-hydroxy-5-(2-methoxyethyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4l

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 3/1 to 1/9, *v/v*). White solid, mp 143–144 °C, procedure b –84% (339 mg). $R_f = 0.43$ (ethyl acetate). IR (KBr) ν_{\max} , cm^{-1} : 3292, 2943, 2876, 1621 (C=O), 1545, 1467, 1107, 1070, 1007, 812. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.14 (dd, $J = 15.0, 7.6$ Hz, 1H, 6- H_a), 3.28 (s, 3H, CH_3), 3.40–3.57 (m, 4H, 6- H_b , NCH_a , CH_2O), 3.89 (dt, $J = 10.6, 5.1$ Hz, 1H, NCH_b), 4.23 (dd, $J = 14.1, 2.9$ Hz, 1H, 8- H_a), 4.35–4.42 (m, 1H, 7-H), 4.47 (dd, $J = 14.1, 5.0$ Hz, 1H, 8- H_b), 5.53 (d, $J = 3.2$ Hz, 1H, OH), 7.21 (s, 1H, 3-H), 7.56–7.63 (m, 2H, Ph 3,5-H), 7.76–7.83 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 46.8 (NCH_2), 52.8 (C-6), 56.0 (C-8), 58.0 (CH_3), 69.5 (7-H), 69.9 (CH_2O), 105.6 (C-3), 120.8 (Ph C-4), 127.1 (Ph C-2,6), 131.7 (Ph C-3,5), 131.8 (Ph C-1), 139.5 (C-3a), 147.9 (C-2), 161.4 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –264.5 (N-5), –174.5 (N-9), –73.9 (N-1). HRMS (ESI) for $\text{C}_{16}\text{H}_{18}\text{BrN}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 402.0424, found m/z 402.0424 and 404.0409.

7-Hydroxy-5-(2-methoxyethyl)-2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4m

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 3.5/1 to 1/9, *v/v*). White solid, mp 147–148 °C, procedure b –80% (274 mg). $R_f = 0.38$ (ethyl acetate). IR (KBr) ν_{\max} , cm^{-1} : 3212, 2982, 2943, 2882, 2838, 1651 (C=O), 1448, 1249, 1020, 834. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.15 (dd, $J = 15.0, 7.4$ Hz, 1H, 6- H_a), 3.28 (s, 3H, OCH_3), 3.39–3.57 (m, 4H, 5- CH_a , CH_2O , 6- H_b), 3.78 (s, 3H, Ph 4- OCH_3), 3.89 (dt, $J = 13.6, 5.2$ Hz, 1H, 5- CH_b), 4.21 (dd, $J = 14.0, 3.1$ Hz, 1H, 8- H_a), 4.34–4.47 (m, 2H, 7-H, 8- H_b), 5.52 (d, $J = 4.2$ Hz, 1H, OH), 6.93–6.99 (m, 2H, Ph 3,5-H), 7.07 (s, 1H, 3-H), 7.73–7.80 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 46.8 (5- CH_2), 52.9 (C-6), 55.1 (CH_3), 55.8 (C-8), 58.1 (OCH_3), 69.6 (C-7), 70.0 (CH_2O), 104.9 (C-3), 114.1 (Ph C-3,5), 125.2 (Ph C-1), 126.4 (Ph C-2,6), 139.2 (C-3a), 148.9 (C-2), 159.0 (Ph C-4), 161.7 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –264.5 (N-5), –176.2 (N-9), –77.0 (N-1). HRMS (ESI) for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{NaO}_4$ ($[\text{M}+\text{Na}]^+$): calcd m/z 354.1424, found m/z 354.1424.

5-Allyl-7-hydroxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4n

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 1/9, *v/v*). White solid, mp 126–127 °C, procedure b –71% (231 mg). $R_f = 0.42$ (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 3346, 2939, 1619 (C=O), 1470, 1431, 1286, 1055, 942, 749, 690. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.09 (dd, $J = 15.0, 7.3$ Hz, 1H, 6- H_a), 3.38 (dd, $J = 15.0, 5.1$ Hz, 1H, 6- H_b), 3.94 (dd, $J = 15.1, 6.4$ Hz, 1H, 5- CH_a), 4.20–4.31 (m, 2H, 5- CH_b , 8- H_a), 4.34–4.42 (m, 1H, 7-H), 4.55 (dd, $J = 14.4, 5.4$ Hz, 1H, 8- H_b), 5.18–5.29 (m, 2H, $\text{CH}_2\text{-CH=CH}_2$), 5.55 (d, $J = 4.2$ Hz, 1H, OH), 5.87 (ddd, $J = 22.5, 10.8, 5.9$ Hz, 1H, $\text{CH}_2\text{-CH=CH}_2$), 7.19 (s, 1H, 3-H), 7.29–7.35 (m, 1H, Ph 4-H), 7.37–7.44 (m, 2H, Ph 3,5-H),

7.81–7.88 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 49.6 (5-CH₂), 51.3 (C-6), 55.9 (C-8), 69.3 (C-7), 105.8 (C-3), 117.8 (CH₂-CH=CH₂), 125.1 (Ph C-2,6), 127.8 (Ph C-4), 128.7 (Ph C-3,5), 132.5 (Ph C-1), 133.5 (CH₂-CH=CH₂), 139.2 (C-3a), 149.0 (C-2), 161.3 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: −263.8 (N-5), −175.4 (N-9), −73.8 (N-1). HRMS (ESI) for C₁₆H₁₇N₃NaO₂ ([M+Na]⁺): calcd m/z 306.1213, found m/z 306.1213.

5-Allyl-2-(4-fluorophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one **4o**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 7/2 to 1/9, *v/v*). White solid, mp 143–144 °C, procedure b −89% (175 mg). R_f = 0.39 (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{max} , cm^{−1}: 3230, 2951, 2892, 1651, 1461, 1440, 933, 837, 816, 756. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.08 (dd, J = 15.0, 7.3 Hz, 1H, 6-H_a), 3.38 (dd, J = 15.0, 5.1 Hz, 1H, 6-H_b), 3.94 (dd, J = 15.2, 6.3 Hz, 1H, 5-CH_a), 4.19–4.32 (m, 2H, 5-CH_b, 8-H_a), 4.34–4.42 (m, 1H, 7-H), 4.54 (dd, J = 14.3, 5.3 Hz, 1H, 8-H_b), 5.18–5.28 (m, J = 14.0 Hz, 2H, CH₂-CH=CH₂), 5.55 (d, J = 4.1 Hz, 1H, OH), 5.87 (dq, J = 10.9, 5.8 Hz, 1H, CH₂-CH=CH₂), 7.20 (s, 1H, 3-H), 7.21–7.29 (m, 2H, Ph 3,5-H), 7.84–7.92 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 49.6 (5-CH₂), 51.3 (C-6), 55.9 (C-8), 69.3 (C-7), 105.7 (C-3), 115.59 (d, $^2J_{\text{CF}}$ = 21.5 Hz, Ph C-3,5), 117.8 (CH₂-CH=CH₂), 127.10 (d, $^3J_{\text{CF}}$ = 8.2 Hz, Ph C-2,6), 129.07 (d, $^4J_{\text{CF}}$ = 3.0 Hz, Ph C-1), 133.5 (CH₂-CH=CH₂), 139.2 (C-3a), 148.1 (C-2), 161.3 (C-4), 161.83 (d, J_{CF} = 244.3 Hz, Ph C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: −264.0 (N-5), −175.1 (N-9), −74.3 (N-1). ^{19}F NMR (376 MHz, DMSO- d_6) δ_{F} ppm: −114.4 (Ph 6-F). HRMS (ESI) for C₁₆H₁₆FN₃NaO₂ ([M+Na]⁺): calcd m/z 324.1119, found m/z 324.1119.

5-Allyl-2-(4-chlorophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one **4p**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 7/2 to 1/9, *v/v*). White solid, mp 179–180 °C, procedure b −92% (188 mg). R_f = 0.42 (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{max} , cm^{−1}: 3363, 2939, 2891, 1620, 1470, 1091, 1053, 939, 812, 753. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.08 (dd, J = 15.0, 7.3 Hz, 1H, 6-H_a), 3.38 (dd, J = 15.0, 5.1 Hz, 1H, 6-H_b), 3.94 (dd, J = 15.1, 6.3 Hz, 1H, 5-CH_a), 4.19–4.42 (m, 3H, 5-CH_b, 7-H, 8-H_a), 4.55 (dd, J = 14.4, 5.4 Hz, 1H, 8-H_b), 5.19–5.29 (m, 2H, CH₂-CH=CH₂), 5.55 (d, J = 4.2 Hz, 1H, OH), 5.86 (ddd, J = 22.5, 10.8, 5.9 Hz, 1H, CH₂-CH=CH₂), 7.23 (s, 1H, 3-H), 7.43–7.51 (m, 2H, Ph 3,5-H), 7.83–7.91 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 49.6 (5-CH₂), 51.2 (C-6), 56.0 (C-8), 69.3 (C-7), 106.0 (C-3), 117.8 (CH₂-CH=CH₂), 126.8 (Ph C-2,6), 128.8 (Ph C-3,5), 131.4 (Ph C-1), 132.3 (Ph C-4), 133.4 (CH₂-CH=CH₂), 139.3 (C-3a), 147.9 (C-2), 161.2 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: −264.1 (N-5), −174.4 (N-9), −73.7 (N-1). HRMS (ESI) for C₁₆H₁₆ClN₃NaO₂ ([M+Na]⁺): calcd m/z 340.0823, found m/z 340.0823.

5-Allyl-2-(4-bromophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one **4r**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient 1/9, *v/v*). White solid, mp 186–187 °C, procedure b −76% (277 mg). R_f = 0.43 (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{max} , cm^{−1}: 3366, 2938, 1621 (C=O), 1469, 1434, 1052, 1006, 933, 811, 752. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.08 (dd, J = 14.9, 7.3 Hz, 1H, 6-H_a), 3.35–3.42 (m, 1H, 6-H_b), 3.94 (dd, J = 15.1, 6.2 Hz, 1H, 5-CH_a), 4.19–4.32 (m, 2H, 5-CH_b, 8-H_a), 4.34–4.41 (m, 1H, 7-H), 4.55 (dd, J = 14.3, 5.3 Hz, 1H, 8-H_b), 5.18–5.28 (m, 2H, CH₂-CH=CH₂), 5.56 (d, J = 4.0 Hz, 1H, OH), 5.81–5.92 (m, 1H, CH₂-CH=CH₂), 7.23 (s, 1H, 3-H), 7.57–7.63 (m, 2H, Ph 3,5-H), 7.78–7.84 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 49.6 (5-CH₂), 51.2 (C-6), 56.0 (C-8), 69.3 (C-7), 106.0 (C-3), 117.8 (CH₂-CH=CH₂), 120.9 (Ph C-4), 127.1 (Ph C-2,6), 131.67 (Ph C-3,5), 131.73 (Ph C-1), 133.4 (CH₂-CH=CH₂), 139.3 (C-3a), 147.9 (C-2), 161.2 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: −263.2

(N-5), -173.1 (N-9), -74.0 (N-1). HRMS (ESI) for $C_{16}H_{16}BrN_3NaO_2$ ($[M+Na]^+$): calcd m/z 384.0318, found m/z 384.0318 and 386.0303.

5-Allyl-7-hydroxy-2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4s**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 1/9, *v/v*). White solid, mp 134–135 °C, procedure b –85% (301 mg). $R_f = 0.35$ (*n*-hexane/ethyl acetate 1.5/3.5, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3284, 2932, 2835, 1624 (C=O), 1467, 1285, 1061, 1026, 935, 828. 1H NMR (400 MHz, DMSO- d_6) δ_H ppm: 3.08 (dd, $J = 15.0$, 7.2 Hz, 1H, 6- H_a), 3.37 (dd, $J = 14.8$, 4.9 Hz, 1H, 6- H_b), 3.78 (s, 3H, Ph 4-OCH₃), 3.94 (dd, $J = 15.1$, 6.4 Hz, 1H, 5-CH_a), 4.20 (dd, $J = 14.3$, 3.8 Hz, 1H, 8- H_a), 4.28 (dd, $J = 15.1$, 5.3 Hz, 1H, 5-CH_b), 4.33–4.40 (m, 1H, 7-H), 4.51 (dd, $J = 14.3$, 5.4 Hz, 1H, 8- H_b), 5.17–5.28 (m, 2H, CH₂-CH=CH₂), 5.54 (d, $J = 4.2$ Hz, 1H, OH), 5.86 (ddd, $J = 22.5$, 10.3, 5.9 Hz, 1H, CH₂-CH=CH₂), 6.93–7.00 (m, 2H, Ph 3,5-H), 7.10 (s, 1H, 3-H), 7.72–7.80 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_C ppm: 49.6 (5-CH₂), 51.3 (C-6), 55.1 (Ph 4-OCH₃), 55.8 (C-8), 69.4 (C-7), 105.2 (C-3), 114.1 (Ph C-3,5), 117.8 (CH₂-CH=CH₂), 125.2 (Ph C-1), 126.4 (Ph C-2,6), 133.5 (CH₂-CH=CH₂), 139.0 (C-3a), 148.9 (C-2), 159.0 (Ph C-4), 161.4 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_N ppm: -176.8 (N-9), -75.9 (N-1). HRMS (ESI) for $C_{17}H_{19}N_3NaO_3$ ($[M+Na]^+$): calcd m/z 336.1319, found m/z 336.1319.

5-Benzyl-7-hydroxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4t**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 1/9, *v/v*). Pale yellow solid, mp 167–168 °C, procedure b –87% (138 mg). $R_f = 0.55$ (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3257, 3143, 2892, 1649 (C=O), 1451, 1235, 765 and 754 (doublet), 705 and 692 (doublet). 1H NMR (400 MHz, DMSO- d_6) δ_H ppm: 3.08 (dd, $J = 14.9$, 7.5 Hz, 1H, 6- H_a), 3.37 (dd, $J = 15.0$, 5.2 Hz, 1H, 6- H_b), 4.12–4.19 (m, 1H, 7-H), 4.24 (dd, $J = 14.4$, 3.5 Hz, 1H, 8- H_a), 4.43–4.56 (m, 2H, 5-CH_a, 8- H_b), 4.96 (d, $J = 14.7$ Hz, 1H, 5-CH_b), 5.51 (d, $J = 4.1$ Hz, 1H, OH), 7.25 (s, 1H, 3-H), 7.29–7.35 (m, 2H, CPh 4-H, CH₂Ph 4-H), 7.36–7.44 (m, 6H, CPh 3,5-H, CH₂Ph 2,3,5,6-H), 7.82–7.88 (m, 2H, CPh 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_C ppm: 50.3 (5-CH₂), 51.3 (C-6), 55.9 (C-8), 69.3 (C-7), 105.9 (C-3), 125.1 (CPh C-2,6), 127.5 (CH₂Ph C-4), 127.8 (CPh C-4), 128.1 (CH₂Ph C-2,6), 128.6 (CH₂Ph C-3,5), 128.7 (CPh C-3,5), 132.5 (CPh C-1), 137.5 (CH₂Ph C-1), 139.0 (C-3a), 149.0 (C-2), 161.7 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_N ppm: -259.1 (N-5), -176.3 (N-9), -73.3 (N-1). HRMS (ESI) for $C_{20}H_{19}N_3NaO_2$ ($[M+Na]^+$): calcd m/z 356.1369, found m/z 356.1370.

5-Benzyl-2-(4-fluorophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **4u**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 4/1 to 1/9, *v/v*). Pale yellow solid, mp 192–193 °C, procedure b –70% (301 mg). $R_f = 0.52$ (*n*-hexane/ethyl acetate 1.5/3.5, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3291, 3144, 2945, 1617 (C=O), 1470, 1442, 1230, 839, 701, 639. 1H NMR (400 MHz, DMSO- d_6) δ_H ppm: 3.07 (dd, $J = 14.9$, 7.5 Hz, 1H, 6- H_a), 3.34–3.40 (m, 1H, 6- H_b), 4.11–4.26 (m, 2H, 7-H, 8- H_a), 4.43–4.55 (m, 2H, 5-CH_a, 8- H_b), 4.96 (d, $J = 14.7$ Hz, 1H, 5-CH_b), 5.50 (d, $J = 4.0$ Hz, 1H, OH), 7.20–7.41 (m, 8H, 3-H, CPh 3,5-H, CH₂Ph 2,3,4,5,6-H), 7.85–7.93 (m, 2H, CPh 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_C ppm: 50.3 (5-CH₂), 51.3 (C-6), 55.9 (C-8), 69.2 (C-7), 105.9 (C-3), 115.61 (d, $^2J_{CF} = 21.5$ Hz, CPh C-3,5), 127.10 (d, $^3J_{CF} = 8.2$ Hz, CPh C-2,6), 127.5 (CH₂Ph C-4), 128.1 (CH₂Ph C-2,6), 128.6 (CH₂Ph C-3,5), 129.06 (d, $^4J_{CF} = 2.8$ Hz, CPh C-1), 137.5 (CH₂Ph C-1), 139.1 (C-3a), 148.2 (C-2), 161.6 (C-4), 161.84 (d, $J_{CF} = 244.3$ Hz, CPh C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_N ppm: -259.9 (N-5), -175.3 (N-9), -74.4 (N-1). ^{19}F NMR (376 MHz, DMSO- d_6) δ_F ppm: -114.3 (CPh 6-F). HRMS (ESI) for $C_{20}H_{18}FN_3NaO_2$ ($[M+Na]^+$): calcd m/z 374.1275, found m/z 374.1275.

5-Benzyl-2-(4-chlorophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4v

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 7/2 to 1/9, *v/v*). White solid, mp 181–182 °C, procedure b –96% (419 mg). $R_f = 0.57$ (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 3246, 2939, 1619 (C=O), 1455, 1434, 1091, 830 and 819 (doublet), 757, 699. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.08 (dd, $J = 14.9, 7.5$ Hz, 1H, 6- H_a), 3.37 (dd, $J = 15.0, 5.0$ Hz, 1H, 6- H_b), 4.11–4.27 (m, 2H, 7-H, 8- H_a), 4.43–4.57 (m, 2H, 5- CH_a , 8- H_b), 4.96 (d, $J = 14.7$ Hz, 1H, 5- CH_b), 5.51 (d, $J = 3.6$ Hz, 1H, OH), 7.28–7.41 (m, 6H, 3-H, CH_2Ph 2,3,4,5,6-H), 7.44–7.50 (m, 2H, CPh 3,5-H), 7.84–7.91 (m, 2H, CPh 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 50.3 (5- CH_2), 51.3 (C-6), 56.0 (C-8), 69.2 (C-7), 106.1 (C-3), 126.8 (CPh C-2,6), 127.5 (CH_2Ph C-4), 128.1 (CH_2Ph C-2,6), 128.6 (CH_2Ph C-3,5), 128.8 (CPh C-3,5), 131.4 (CPh C-1), 132.3 (CPh C-4), 137.5 (CH_2Ph C-1), 139.2 (C-3a), 147.9 (C-2), 161.6 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –259.6 (N-5), –174.8 (N-9), –73.4 (N-1). HRMS (ESI) for $\text{C}_{20}\text{H}_{18}\text{ClN}_3\text{NaO}_2$ ($[\text{M}+\text{Na}]^+$): calcd m/z 390.0980, found m/z 390.0980.

5-Benzyl-2-(4-bromophenyl)-7-hydroxy-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4w

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 1/9, *v/v*). Pale yellow solid, mp 157–158 °C, procedure b –72% (287 mg). $R_f = 0.57$ (*n*-hexane/ethyl acetate 3/7, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 3270, 1619 (C=O), 1460, 1429, 1247, 1068, 1009, 816, 756, 701. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.08 (dd, $J = 14.9, 7.6$ Hz, 1H, 6- H_a), 3.34–3.41 (m, 1H, 6- H_b), 4.12–4.18 (m, 1H, 7-H), 4.20–4.27 (m, 1H, 8- H_a), 4.46 (d, $J = 14.7$ Hz, 1H, 5- CH_a), 4.52 (dd, $J = 14.4, 5.3$ Hz, 1H, 8- H_b), 4.96 (d, $J = 14.7$ Hz, 1H, 5- CH_b), 5.51 (d, $J = 4.1$ Hz, 1H, OH), 7.28–7.34 (m, 2H, 3-H, CH_2Ph 4-H), 7.35–7.39 (m, 4H, CH_2Ph 2,3,5,6-H), 7.56–7.64 (m, 2H, CPh 3,5-H), 7.78–7.85 (m, 2H, CPh 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 50.4 (5- CH_2), 51.3 (C-6), 56.0 (C-8), 69.2 (C-7), 106.1 (C-3), 120.9 (CPh C-4), 127.1 (CPh C-2,6), 127.5 (CH_2Ph C-4), 128.2 (CH_2Ph C-3,5), 128.6 (CH_2Ph C-2,6), 131.68 (CPh C-3,5), 131.72 (CPh C-1), 137.5 (CH_2Ph C-1), 139.2 (C-3a), 148.0 (C-2), 161.6 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –259.5 (N-5), –174.5 (N-9), –73.7 (N-1). HRMS (ESI) for $\text{C}_{20}\text{H}_{18}\text{BrN}_3\text{NaO}_2$ ($[\text{M}+\text{Na}]^+$): calcd m/z 434.0475, found m/z 434.0475 and 436.0445.

5-Benzyl-7-hydroxy-2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one 4x

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate gradient from 3.5/1 to 1/9, *v/v*). White solid, mp 179–180 °C, procedure b –72% (313 mg). $R_f = 0.46$ (*n*-hexane/ethyl acetate 1.5/3.5, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 3204, 1651 (C=O), 1462, 1436, 1250, 1180, 1029, 833, 753, 705. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.07 (dd, $J = 14.9, 7.5$ Hz, 1H, 6- H_a), 3.36–3.40 (m, 1H, 6- H_b), 3.78 (s, 3H, - OCH_3), 4.11–4.24 (m, 2H, 7-H, 8- H_a), 4.42–4.53 (m, 2H, 5- CH_a , 8- H_b), 4.96 (d, $J = 14.7$ Hz, 1H, 5- CH_b), 5.50 (s, 1H, OH), 6.94–7.00 (m, 2H, CPh 3,5-H), 7.15 (s, 1H, 3-H), 7.28–7.34 (m, 1H, CH_2Ph 4-H), 7.35–7.41 (m, 4H, CH_2Ph 2,3,5,6-H), 7.74–7.81 (m, 2H, CPh 2,6-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 50.4 (5- CH_2), 51.4 (C-6), 55.1 (OCH_3), 55.8 (C-8), 69.3 (C-7), 105.3 (C-3), 114.1 (CPh C-3,5), 125.1 (CPh C-1), 126.4 (CPh C-2,6), 127.5 (CH_2Ph C-4), 128.1 (CH_2Ph C-2,6), 128.6 (CH_2Ph C-3,5), 137.6 (CH_2Ph C-1), 138.9 (C-3a), 149.0 (C-2), 159.0 (CPh C-4), 161.8 (C-4). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: –258.9 (N-5), –176.9 (N-9), –75.4 (N-1). HRMS (ESI) for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 386.1475, found m/z 386.1475.

3.2.4. Synthesis of Ethyl 1-(oxiran-2-ylmethyl)-1H-indole-2-carboxylates (6a–e) and Ethyl 1-(oxiran-2-ylmethyl)-1H-benzo[d]imidazole-2-carboxylate (6f)

Procedure a. Indole-2-carboxylate **5a–e** (1 eq) was dissolved in dry dimethyl formamide (0.2 M) and KOH (3 eq; flakes) was added followed by 2-(chloromethyl)oxirane (1.5 eq). The reaction mixture was stirred at 40 °C for 1 h under argon atmosphere. Upon completion, the mixture was concentrated to approximately 1/3 volume, diluted with

ethyl acetate, and washed with brine. Organic layer was separated, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

Procedure b. Benzimidazole-2-carboxylate **5f** (1 eq) was dissolved in dry dimethyl formamide (0.3 M) and NaH (1.5 eq; 60% dispersion in mineral oil) was added followed by 2-(chloromethyl)oxirane (1.5 eq). The reaction mixture was stirred at 60 °C for 4 h. Upon completion, the reaction mixture was cooled to 0 °C, quenched with water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

Ethyl 1-(oxiran-2-ylmethyl)-1*H*-indole-2-carboxylate **6a**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 8/1, *v/v*). White solid, mp 47–49 °C, procedure a –73% (94 mg). $R_f = 0.29$ (*n*-hexane/ethyl acetate 6/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3064, 2974, 2928, 1713 (C=O), 1408, 1265, 1205, 1140, 1096, 744. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.41 (t, $J = 7.1$ Hz, 3H, CH_3), 2.49–2.53 (m, 1H, Ox CH_aH_b), 2.77 (t, $J = 4.2$ Hz, 1H, Ox CH_aH_b), 3.33–3.39 (m, 1H, Ox CH), 4.38 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.56 (dd, $J = 15.1, 5.0$ Hz, 1H, NCH_aH_b), 5.03 (dd, $J = 15.1, 2.4$ Hz, 1H, NCH_aH_b), 7.14–7.18 (m, 1H, 5-H), 7.34–7.37 (m, 2H, 3-H, 6-H), 7.45–7.47 (m, 1H, 7-H), 7.66–7.68 (m, 1H, 4-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 14.5 (CH_3), 45.5 (Ox CH_aH_b), 46.2 (NCH_aH_b), 51.6 (Ox CH), 60.8 (CH_2CH_3), 110.9 (C-7), 111.1 (C-3), 121.1 (C-5), 122.7 (C-4), 125.5 (C-6), 126.1 (C-3a), 127.7 (C-2), 140.0 (C-7a), 162.3 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –250.9 (N). HRMS (ESI) for $\text{C}_{14}\text{H}_{16}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 246.1125, found m/z 246.1119.

Ethyl 5-fluoro-1-(oxiran-2-ylmethyl)-1*H*-indole-2-carboxylate **6b**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 8/1, *v/v*). White solid, mp 65–66 °C, procedure a –39% (50 mg). $R_f = 0.19$ (*n*-hexane/ethyl acetate 6/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 2974, 2930, 1713 (C=O), 1527, 1266, 1246, 1177, 1091, 756. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.41 (t, $J = 7.1$ Hz, 3H, CH_3), 2.45–2.53 (m, 1H, Ox CH_aH_b), 2.79 (t, $J = 4.2$ Hz, 1H, Ox CH_aH_b), 3.32–3.40 (m, 1H, Ox CH), 4.38 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.47 (dd, $J = 15.2, 5.3$ Hz, 1H, NCH_aH_b), 5.08 (dd, $J = 15.2, 2.4$ Hz, 1H, NCH_aH_b), 7.07–7.15 (m, 1H, 6-H), 7.24–7.33 (m, 2H, 3-H, 7-H), 7.38–7.45 (m, 1H, 4-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 14.5 (CH_3), 45.3 (Ox CH_aH_b), 46.6 (NCH_aH_b), 51.7 (Ox CH), 61.0 (CH_2CH_3), 106.7 (d, $J = 23.2$ Hz, C-7), 110.7 (d, $J = 5.1$ Hz, C-3), 112.1 (d, $J = 10.1$ Hz, C-4), 114.6 (d, $J = 27.3$ Hz, C-6), 126.1 (d, $J = 11.1$ Hz, C-3a), 129.0 (C-2), 136.7 (C-7a), 158.4 (d, $J = 238.4$ Hz, C-5), 162.0 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –250.9 (N). ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ_{F} ppm: –127.7 (F). HRMS (ESI) for $\text{C}_{14}\text{H}_{15}\text{FNO}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 264.1030, found m/z 264.1031.

Ethyl 5-chloro-1-(oxiran-2-ylmethyl)-1*H*-indole-2-carboxylate **6c**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 8/1, *v/v*). White solid, mp 79–80 °C, procedure a –69% (72 mg). $R_f = 0.23$ (*n*-hexane/ethyl acetate 6/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 2984, 2928, 1703 (C=O), 1517, 1457, 1252, 1199, 763. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.42 (t, $J = 7.1$ Hz, 3H, CH_3), 2.48 (dd, $J = 4.4, 2.6$ Hz, 1H, Ox CH_aH_b), 2.78 (t, $J = 4.3$ Hz, 1H, Ox CH_aH_b), 3.32–3.38 (m, 1H, Ox CH), 4.38 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.47 (dd, $J = 15.2, 5.4$ Hz, 1H, NCH_aH_b), 5.07 (dd, $J = 15.2, 2.6$ Hz, 1H, NCH_aH_b), 7.25–7.26 (m, 1H, 3-H), 7.28–7.30 (m, 1H, 6-H), 7.39–7.41 (m, 1H, 7-H), 7.62–7.63 (m, 1H, 4-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 14.5 (CH_3), 45.3 (Ox CH_aH_b), 46.5 (NCH_aH_b), 51.6 (Ox CH), 61.1 (CH_2CH_3), 110.3 (C-3), 112.3 (C-7), 121.7 (C-4), 125.9 (C-6), 126.8 (C-5), 126.9 (C-3a), 128.8 (C-2), 138.3 (C-7a), 162.0 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –250.0 (N). HRMS (ESI) for $\text{C}_{14}\text{H}_{15}\text{ClNO}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 280.0735, found m/z 280.0733.

Ethyl 5-methyl-1-(oxiran-2-ylmethyl)-1H-indole-2-carboxylate 6d

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 8/1, *v/v*). White solid, mp 72–74 °C, procedure a –75% (96 mg). $R_f = 0.27$ (*n*-hexane/ethyl acetate 6/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2976, 1706 (C=O), 1408, 1263, 1211, 1128, 1096, 763. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.41 (t, $J = 7.1$ Hz, 3H, CH_2CH_3), 2.44 (s, 3H, 5- CH_3), 2.49 (dd, $J = 4.4, 2.6$ Hz, 1H, Ox CH_aH_b), 2.76 (t, $J = 4.4$ Hz, 1H, Ox CH_aH_b), 3.32–3.37 (m, 1H, Ox CH), 4.37 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.55 (dd, $J = 15.1, 5.0$ Hz, 1H, NCH_aH_b), 4.99 (dd, $J = 15.1, 3.2$ Hz, 1H, NCH_aH_b), 7.16–7.20 (m, 1H, 6-H), 7.22–7.27 (m, 1H, 3-H), 7.33–7.37 (m, 1H, 7-H), 7.42–7.48 (m, 1H, 4-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 14.5 (CH_2CH_3), 21.5 (5- CH_3), 45.5 (Ox CH_aH_b), 46.2 (NCH_aH_b), 51.7 (Ox CH), 60.7 (CH_2CH_3), 110.59 (C-7), 110.62 (C-3), 121.9 (C-4), 126.3 (C-3a), 127.5 (C-6), 127.6 (C-2), 130.4 (C-5), 138.5 (C-7a), 162.3 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –251.8 (N). HRMS (ESI) for $\text{C}_{15}\text{H}_{18}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 260.1281, found m/z 260.1277.

Ethyl 3-methyl-1-(oxiran-2-ylmethyl)-1H-indole-2-carboxylate 6e

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate gradient from 9/1 to 8/1, *v/v*). Colorless liquid, procedure a –47% (60 mg). $R_f = 0.14$ (petroleum ether/ethyl acetate 10/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 1698 (C=O), 1273, 1250, 1208, 1129, 1111, 741. ^1H NMR (500 MHz, CDCl_3) δ_{H} ppm: 1.44 (t, $J = 7.2$ Hz, 3H, CH_2CH_3), 2.49 (dd, $J = 4.9, 2.8$ Hz, 1H, Ox CH_aH_b), 2.59 (s, 3H, 5- CH_3), 2.74–2.77 (m, 1H, Ox CH_aH_b), 3.33–3.37 (m, 1H, Ox CH), 4.42 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.50 (dd, $J = 15.3, 5.2$ Hz, 1H, NCH_aH_b), 4.94 (dd, $J = 15.3, 3.4$ Hz, NCH_aH_b), 7.13–7.17 (m, 1H, 5-H), 7.33–7.37 (m, 1H, 6-H), 7.39–7.43 (m, 1H, 7-H), 7.64–7.69 (m, 1H, 4-H). ^{13}C NMR (125 MHz, CDCl_3) δ_{C} ppm: 11.0 (3- CH_3), 14.5 (CH_2CH_3), 45.4 (Ox CH_aH_b), 46.4 (NCH_aH_b), 51.8 (Ox CH), 60.6 (CH_2CH_3), 110.6 (C-7), 120.2 (C-5), 120.8 (C-4), 121.5 (C_q), 124.6 (C_q), 125.7 (C-6), 127.4 (C_q), 139.1 (C_q), 163.2 (COO). ^{15}N NMR (40 MHz, CDCl_3) δ_{N} ppm: –254.7 (N). HRMS (ESI) for $\text{C}_{15}\text{H}_{18}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 260.1281, found m/z 260.1276.

Ethyl 1-(oxiran-2-ylmethyl)-1H-benzo[d]imidazole-2-carboxylate 6f

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate gradient from 1/1 to 2/3, *v/v*). White solid, mp 49–52 °C, procedure b –33% (86 mg). $R_f = 0.37$ (petroleum ether/ethyl acetate 1/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2360, 2341, 1709 (C=O), 1494, 1457, 1410, 1338, 1283, 1202, 1138, 743. ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ_{H} ppm: 1.34 (t, $J = 7.2$ Hz, 3H, CH_3), 2.42–2.45 (m, 1H, Ox CH_aH_b), 2.72 (t, $J = 4.4$ Hz, Ox CH_aH_b), 3.33–3.38 (m, 1H, Ox CH), 4.37 (q, $J = 7.1$ Hz, 2H, CH_2CH_3), 4.58 (dd, $J = 15.1, 8.7$ Hz, 1H, NCH_aH_b), 5.03 (dd, $J = 15.3, 3.1$ Hz, NCH_aH_b), 7.29–7.34 (m, 1H, 5-H), 7.37–7.42 (m, 1H, 6-H), 7.69–7.72 (m, 1H, 7-H), 7.74–7.78 (m, 1H, 4-H). ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ_{C} ppm: 14.5 (CH_3), 45.2 (Ox CH_aH_b), 46.8 (NCH_aH_b), 50.9 (Ox CH), 62.2 (CH_2CH_3), 112.5 (C-7), 121.4 (C-4), 124.0 (C-5), 125.7 (C-6), 136.8 (C_q), 141.5 (C_q), 141.6 (C_q), 160.1 (COO). ^{15}N NMR (40 MHz, $\text{DMSO}-d_6$) δ_{N} ppm: –229.8 (N). HRMS (ESI) for $\text{C}_{13}\text{H}_{14}\text{N}_2\text{O}_3$ ($[\text{M}+\text{H}]^+$): calcd m/z 247.1077, found m/z 247.1071.

3.2.5. Synthesis of 4-Hydroxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-*a*]indol-1-ones (7a–f) and 4-Hydroxy-2,3,4,5-tetrahydro-1H-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one (7g)

Procedure a. Ethyl 1-(oxiran-2-ylmethyl)-1H-indole-2-carboxylate **6a–e** or ethyl 1-(oxiran-2-ylmethyl)-1H-benzo[*d*]imidazole-2-carboxylate **6f** (1 eq) was dissolved in 7M ammonia (100 eq) solution in methanol, sealed in a pressure tube and stirred at 70 °C for 18 h. After completion, the reaction mixture was cooled to 0 °C, quenched with water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

Procedure b. To a solution of ethyl 1-(oxiran-2-ylmethyl)-1H-indole-2-carboxylate **7a** (1eq) in methanol (5 M) benzylamine (3 eq) was added, the reaction mixture was sealed in a pressure tube and stirred at 70 °C for 18 h. After completion, the reaction mixture

was poured into water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

4-Hydroxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indol-1-one **7a**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, *v/v*). White solid, decomp. 216 °C, procedure a –93% (82 mg). $R_f = 0.45$ (dichloromethane/methanol 9/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3318, 3194, 3049, 2895, 1660 (C=O), 1643 (C=O), 1549, 1461, 1407, 740. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 2.83 (dt, $J = 12.0, 5.6$ Hz, 1H, 3- H_a), 3.21 (dt, $J = 11.3, 5.4$ Hz, 1H, 3- H_b), 4.18–4.28 (m, 2H, 5- H_a , 4-H), 4.42 (dd, $J = 13.9, 4.1$ Hz, 1H, 5- H_b), 5.37 (d, $J = 3.8$ Hz, 1H, OH), 6.93 (s, 1H, 11-H), 7.06–7.10 (m, 1H, 9-H), 7.25–7.29 (m, 1H, 8-H), 7.55–7.57 (m, 1H, 7-H), 7.62–7.64 (m, 1H, 10-H), 8.08–8.10 (m, 1H, NH). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 45.6 (C-3), 48.2 (C-5), 69.5 (C-4), 105.3 (C-11), 110.5 (C-7), 119.9 (C-9), 121.6 (C-10), 123.5 (C-8), 126.0 (C-10a), 134.7 (C-11a), 137.5 (C-6a), 165.5 (C-1). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –272.6 (N-2), –249.8 (N-6). HRMS (ESI) for $\text{C}_{12}\text{H}_{13}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 217.0972, found m/z 217.0969.

9-Fluoro-4-hydroxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indol-1-one **7b**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, *v/v*). White solid, decomp. 220 °C, procedure a –63% (56 mg). $R_f = 0.55$ (dichloromethane/methanol 9/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3335, 3283, 3200, 3047, 1647 (C=O), 1548, 1408, 1203, 796. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 2.78–2.87 (m, 1H, 3- H_a), 3.16–3.26 (m, 1H, 3- H_b), 4.16–4.30 (m, 2H, 5- H_a , 4-H), 4.43 (dd, $J = 14.0, 4.2$ Hz, 1H, 5- H_b), 5.38 (d, $J = 4.0$ Hz, 1H, OH), 6.91 (s, 1H, 11-H), 7.08–7.19 (m, 1H, 8-H), 7.36–7.43 (m, 1H, 10-H), 7.56–7.63 (m, 1H, 7-H), 8.12–8.20 (m, 1H, NH). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 45.6 (C-3), 48.5 (C-5), 69.5 (C-4), 105.0 (d, $^4J_{\text{CF}} = 5.1$ Hz, C-11), 105.8 (d, $^2J_{\text{CF}} = 23.3$ Hz, C-10), 111.9 (d, $^3J_{\text{CF}} = 9.8$ Hz, C-7), 112.1 (d, $^2J_{\text{CF}} = 26.6$ Hz, C-8), 126.1 (d, $^3J_{\text{CF}} = 10.6$ Hz, C-10a), 134.2 (C-6a), 136.3 (C-11a), 157.2 (d, $J_{\text{CF}} = 233.1$ Hz, C-9), 165.2 (C-1). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –271.8 (N-2), –250.1 (N-6). HRMS (ESI) for $\text{C}_{12}\text{H}_{12}\text{FN}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 235.0877, found m/z 235.0876.

9-Chloro-4-hydroxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indol-1-one **7c**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, *v/v*). White solid, decomp. 210 °C, procedure a –84% (75 mg). $R_f = 0.52$ (dichloromethane/methanol 9/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3325, 3275, 3191, 3046, 1660 (C=O), 1643 (C=O), 1545, 1408, 797. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 2.86–2.75 (m, 1H, 3- H_a), 3.27–3.14 (m, 1H, 3- H_b), 4.29–4.16 (m, 2H, 4-H, 5- H_a), 4.43 (dd, $J = 13.8, 3.9$ Hz, 1H, 5- H_b), 5.39 (d, $J = 3.8$ Hz, 1H, OH), 6.91 (s, 1H, 11-H), 7.24–7.31 (m, 1H, 8-H), 7.57–7.65 (m, 1H, 7-H), 7.68–7.73 (m, 1H, 10-H), 8.14–8.22 (m, 1H, NH). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 45.5 (C-3), 48.5 (C-5), 69.4 (C-4), 104.7 (C-11), 112.3 (7-C), 120.6 (C-10), 123.5 (C-8), 124.4 (C-9), 127.0 (C-10a), 135.9 (C-6a), 136.1 (C-11a), 165.1 (C-1). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –271.5 (N-2), –248.7 (N-6). HRMS (ESI) for $\text{C}_{12}\text{H}_{12}\text{ClN}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 251.0582, found m/z 251.0580.

4-Hydroxy-9-methyl-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indol-1-one **7d**

Purified by column chromatography on silica gel (dichloromethane/methanol 100/5, *v/v*). White solid, decomp. 225 °C, procedure a –86% (76 mg). $R_f = 0.66$ (dichloromethane/methanol 9/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3319, 3194, 3046, 1659 (C=O), 1640 (C=O), 1552, 1463, 1407, 790. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 2.38 (s, 3H, CH_3), 2.78–2.87 (m, 1H, 3- H_a), 3.15–3.24 (m, 1H, 3- H_b), 4.16 (dd, $J = 14.3, 4.3$ Hz, 1H, 5- H_a), 4.20–4.27 (m, 1H, 4-H), 4.38 (dd, $J = 14.2, 4.7$ Hz, 1H, 5- H_b), 5.35 (d, $J = 4.1$ Hz, 1H, OH), 6.83 (s, 1H, 11-H), 7.06–7.14 (m, 1H, 8-H), 7.37–7.42 (m, 1H, 10-H), 7.41–7.47 (m, 1H, 7-H), 8.02–8.09 (m, 1H, NH). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 21.0 (CH_3), 45.7 (C-3), 48.3 (C-5), 69.6 (C-4), 104.8 (C-11), 110.2 (C-7), 120.9 (C-10), 125.3 (C-8), 126.2 (C-9), 128.5 (C-10a), 134.6 (C-11a),

136.0 (C-6a), 165.6 (C-1). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: -273.1 (N-2), -250.9 (N-6). ^{19}F NMR (376 MHz, DMSO- d_6) δ_{F} ppm: -123.9 (F). HRMS (ESI) for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 231.1128, found m/z 231.1124.

4-Hydroxy-11-methyl-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-*a*]indol-1-one 7e

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate/methanol gradient from 1/3/0 to 5/20/1, $v/v/v$). White solid, decomp. 218 °C, procedure a -66% (66 mg). R_f = 0.42 (ethyl acetate/methanol 10/1, v/v). IR (KBr) ν_{max} , cm^{-1} : 3308, 1631 (C=O), 1556, 1461, 1418, 1383, 1362, 1341, 1329, 1259, 1066, 733. ^1H NMR (500 MHz, DMSO- d_6) δ_{H} ppm: 2.36 (s, 3H, CH₃), 2.76 (dt, J = 14.4, 6.0 Hz, 1H, 3-H_a), 3.13 (dt, J = 14.4, 5.8 Hz, 1H, 3-H_b), 4.10 (dd, J = 14.2, 4.4 Hz, 1H, 5-H_a), 4.12–4.19 (m, 1H, 4-H), 4.32 (dd, J = 14.4, 4.9 Hz, 1H, 5-H_b), 5.30 (d, J = 4.0 Hz, 1H, OH), 7.02–7.10 (m, 1H, 9-H), 7.22–7.29 (m, 1H, 8-H), 7.47–7.52 (m, 1H, 7-H), 7.57–7.62 (m, 1H, 10-H), 7.97–8.02 (m, 1H, NH). ^{13}C NMR (125 MHz, DMSO- d_6) δ_{C} ppm: 9.6 (CH₃), 46.1 (C-3), 48.6 (C-5), 69.4 (C-4), 110.6 (C-7), 115.5 (C_q), 119.6 (C-9), 120.3 (C-10), 124.3 (C-8), 127.4 (C_q), 130.3 (C_q), 137.0 (C_q), 166.3 (C-1). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: -271.4 (N-2), -254.4 (N-6). HRMS (ESI) for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 231.1128, found m/z 231.1126.

2-Benzyl-4-hydroxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-*a*]indol-1-one 7f

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate gradient from 7/1 to 1/6, v/v). White solid, mp 183–184 °C, procedure b -87% (142.1 mg). R_f = 0.53 (petroleum ether/ethyl acetate 3/1, v/v). IR (KBr) ν_{max} , cm^{-1} : 3313 (OH), 2360, 2341, 1610 (C=O), 1541, 1421, 1079, 740. ^1H NMR (400 MHz, DMSO- d_6) δ_{H} ppm: 3.01 (dd, J = 14.8, 7.4 Hz, 1H, 3-H_a), 3.31 (dd, J = 14.8, 5.2 Hz, 1H, 3-H_b), 4.06–4.14 (m, 1H, 4-H), 4.23 (dd, J = 14.6, 3.8 Hz, 1H, 5-H_a), 4.38 (dd, J = 14.6, 4.9 Hz, 1H, 5-H_b), 4.46 (d, J = 14.6 Hz, 1H, 2-CH_a), 5.00 (d, J = 14.6 Hz, 1H, 2-CH_b), 5.40 (d, J = 4.0 Hz, 1H, OH), 6.99–7.01 (m, 1H, 11-H), 7.05–7.11 (m, 1H, 9-H), 7.23–7.35 (m, 2H, 8-H, CH₂Ph 4-H), 7.36–7.41 (m, 4H, CH₂Ph 2,3,5,6-H), 7.50–7.57 (m, 1H, 7-H), 7.61–7.67 (m, 1H, 10-H). ^{13}C NMR (101 MHz, DMSO- d_6) δ_{C} ppm: 48.1 (C-5), 50.4 (CH₂Ph), 51.4 (C-3), 69.1 (C-4), 105.5 (C-11), 110.4 (C-7), 120.0 (C-9), 121.6 (C-10), 123.6 (C-8), 126.0 (C-10a), 127.4 (CH₂Ph C-4), 128.2 (CH₂Ph C-3,5), 128.7 (CH₂Ph C-2,6), 134.3 (C-11a), 137.3 (C-6a), 137.9 (CH₂Ph C-1), 163.9 (C-1). ^{15}N NMR (40 MHz, DMSO- d_6) δ_{N} ppm: -255.0 (N-6), -265.7 (N-2). HRMS (ESI) for $\text{C}_{19}\text{H}_{19}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 307.1441, found m/z 307.1388.

4-Hydroxy-2,3,4,5-tetrahydro-1H-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one 7g

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate/methanol gradient from 1/5/0 to 1/12/1, $v/v/v$). White solid, decomp. 190 °C, procedure a -19% (18 mg). R_f = 0.21 (ethyl acetate/methanol 9/1, v/v). IR (KBr) ν_{max} , cm^{-1} : 3379, 3220, 1676 (C=O), 1522, 1466, 1458, 1418, 1336, 1079, 741. ^1H NMR (500 MHz, DMSO- d_6) δ_{H} ppm: 2.75 (dt, J = 15.0 Hz, 6.1 Hz, 1H, 3-H_a), 3.21 (dt, J = 14.7 Hz, 5.8 Hz, 1H, 3-H_b), 4.22–4.31 (m, 2H, 5-H_a, 4-H), 4.49 (dd, J = 14.1 Hz, 4.3 Hz, 1H, 5-H_b), 5.35–5.55 (br s, 1H, OH), 7.23–7.28 (m, 1H, 9-H), 7.31–7.37 (m, 1H, 8-H), 7.63–7.73 (m, 2H, 7-H, 10-H), 8.56–8.63 (m, 1H, NH). ^{13}C NMR (125 MHz, DMSO- d_6) δ_{C} ppm: 45.4 (C-3), 48.2 (C-5), 69.9 (C-4), 111.5 (C-7), 120.7 (C-10), 123.1 (C-9), 124.6 (C-8), 135.2 (C_q), 142.0 (C_q), 147.4 (C_q), 163.2 (C-1). HRMS (ESI) for $\text{C}_{11}\text{H}_{12}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 218.0924, found m/z 218.0918.

3.2.6. Synthesis of *O*-Alkylated 5-Substituted

7-Hydroxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-ones (**8a–f**) and 2-Benzyl-4-hydroxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-*a*]indol-1-one (**9a,b**)

Pyrazolo-diazepinone **4i,n,t** or indole-diazepinone **7f** (1 eq) was dissolved in dimethyl formamide (0.1 M) and NaH (1.5 eq; 60% dispersion in mineral oil) was added followed by appropriate alkylating agent (1.5 eq). The reaction mixture was stirred at 25–50 °C for 5–8 h. Upon completion, the mixture was concentrated to approximately 1/3 volume, diluted with ethyl acetate, and washed with brine. Organic layer was dried over anhydrous

Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by column chromatography.

7-Methoxy-5-(2-methoxyethyl)-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **8a**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 1/1, *v/v*). White solid, mp 88–89 °C, 77% (104 mg). $R_f = 0.41$ (*n*-hexane/ethyl acetate 1/4, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3120, 2933, 2890, 2828, 1638 (C=O), 1470, 1354, 1016, 771, 700. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 3.23 (dd, $J = 15.2, 7.6$ Hz, 1H, 5- CH_a), 3.29 (s, 3H, CH_2OCH_3), 3.37 (s, 3H, 7- OCH_3), 3.39–3.47 (m, 1H, 6- H_a), 3.51–3.62 (m, 3H, 5- CH_b , CH_2O), 3.90 (dt, $J = 13.6, 5.2$ Hz, 1H, 6- H_b), 4.05–4.12 (m, 1H, 7-H), 4.46 (qd, $J = 14.7, 4.3$ Hz, 2H, 8- H_aH_b), 7.18 (s, 1H, 3-H), 7.29–7.35 (m, 1H, Ph 4-H), 7.38–7.45 (m, 2H, Ph 3,5-H), 7.8–7.87 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 46.6 (C-6), 50.0 (5- CH_2), 52.1 (C-8), 56.3 (7- OCH_3), 58.0 (CH_2OCH_3), 69.8 (CH_2O), 79.2 (C-7), 105.5 (C-3), 125.2 (Ph C-2,6), 127.8 (Ph C-4), 128.7 (Ph C-3,5), 132.4 (Ph C-1), 139.3 (C-3a), 149.1 (C-2), 161.6 (C-4). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –266.0 (N-5), –176.2 (N-9), –74.1 (N-1). HRMS (ESI) for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{NaO}_3$ ($[\text{M}+\text{Na}]^+$): calcd m/z 338.1475, found m/z 338.1475.

5-Allyl-7-methoxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **8b**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 3.5/1, *v/v*). White solid, mp 89–90 °C, 84% (78 mg). $R_f = 0.47$ (*n*-hexane/ethyl acetate 1/1, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 2984, 2929, 2826, 1657 (C=O), 1461, 1243, 1206, 1089, 770, 697. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 3.19 (dd, $J = 15.2, 6.9$ Hz, 1H, 6- H_a), 3.36 (s, 3H, CH_3), 3.46 (dd, $J = 15.2, 5.0$ Hz, 1H, 6- H_b), 3.97 (dd, $J = 15.1, 6.2$ Hz, 1H, 5- CH_a), 4.09 (dt, $J = 10.4, 5.1$ Hz, 1H, 7-H), 4.23 (dd, $J = 15.1, 5.5$ Hz, 1H, 5- CH_b), 4.40 (dd, $J = 14.7, 4.0$ Hz, 1H, 8- H_a), 4.58 (dd, $J = 14.7, 5.4$ Hz, 1H, 8- H_b), 5.18–5.31 (m, 2H, $\text{CH}_2\text{-CH=CH}_2$), 5.81–5.92 (m, 1H, $\text{CH}_2\text{-CH=CH}_2$), 7.20 (s, 1H, 3-H), 7.29–7.36 (m, 1H, Ph 4-H), 7.37–7.45 (m, 2H, Ph 3,5-H), 7.81–7.88 (m, 2H, Ph 2,6-H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 48.4 (C-6), 49.6 (5- CH_2), 52.3 (C-8), 56.3 (CH_3), 78.9 (C-7), 105.8 (C-3), 117.9 ($\text{CH}_2\text{-CH=CH}_2$), 125.1 (Ph C-2,6), 127.9 (Ph C-4), 128.7 (Ph C-3,5), 132.4 (Ph C-1), 133.4 ($\text{CH}_2\text{-CH=CH}_2$), 139.1 (C-3a), 149.1 (C-2), 161.3 (C-4). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –176.0 (N-9), –73.9 (N-1). HRMS (ESI) for $\text{C}_{17}\text{H}_{19}\text{N}_3\text{NaO}_2$ ($[\text{M}+\text{Na}]^+$): calcd m/z 320.1369, found m/z 320.1370.

5-Benzyl-7-methoxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **8c**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 7/2, *v/v*). Pale yellow solid, mp 176–177 °C, 70% (57 mg). $R_f = 0.41$ (*n*-hexane/ethyl acetate 3/2, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 3146, 2988, 2928, 2871, 1651 (C=O), 1449, 1241, 1101, 764, 695. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 3.19 (dd, $J = 15.2, 7.1$ Hz, 1H, 6- H_a), 3.28 (s, 3H, CH_3), 3.48 (dd, $J = 15.2, 5.0$ Hz, 1H, 6- H_b), 3.86–3.93 (m, 1H, 7-H), 4.42 (dd, $J = 14.8, 3.8$ Hz, 1H, 8- H_a), 4.48–4.59 (m, 2H, 8- H_b , 5- CH_a), 4.88 (d, $J = 14.7$ Hz, 1H, 5- CH_b), 7.26 (s, 1H, 3-H), 7.30–7.35 (m, 2H, CPh 4-H, CH_2Ph 4-H), 7.36–7.44 (m, 6H, CPh 3,5-H, CH_2Ph 2,3,5,6-H), 7.82–7.87 (m, 2H, CPh 2,6-H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ_{C} ppm: 48.6 (C-6), 50.4 (5- CH_2), 52.3 (C-8), 56.3 (CH_3), 78.8 (C-7), 106.0 (C-3), 125.1 (CPh C-2,6), 127.5 (CH_2Ph C-4), 127.9 (CPh C-4), 128.1 (CH_2Ph C-2,6), 128.6 (CH_2Ph C-3,5), 128.7 (CPh C-3,5), 132.4 (CPh C-1), 137.4 (CH_2Ph C-1), 139.0 (C-3a), 149.2 (C-2), 161.7 (C-4). ^{15}N NMR (40 MHz, $\text{DMSO-}d_6$) δ_{N} ppm: –261.2 (N-5), –176.7 (N-9), –74.1 (N-1). HRMS (ESI) for $\text{C}_{21}\text{H}_{21}\text{N}_3\text{NaO}_2$ ($[\text{M}+\text{Na}]^+$): calcd m/z 370.1526, found m/z 370.1526.

7-Ethoxy-5-(2-methoxyethyl)-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one **8d**

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate/methanol 1/1/0.05, *v/v*). Yellowish resin, 75% (118 mg). $R_f = 0.54$ (*n*-hexane/ethyl acetate 1/4, *v/v*). IR (KBr) ν_{max} , cm^{-1} : 2977, 2931, 2893, 1647 (C=O), 1461, 1440, 1104, 1077, 769, 695. ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ_{H} ppm: 1.14 (t, $J = 7.0$ Hz, 3H, 7- OCH_2CH_3), 3.24 (dd, $J = 15.3,$

7.4 Hz, 1H, 5-CH_a), 3.29 (s, 3H, CH₂OCH₃), 3.41–3.49 (m, 1H, 6-H_a), 3.51–3.68 (m, 5H, 5-CH_b, CH₂OCH₃, 7-OCH₂), 3.88 (dt, *J* = 13.5, 5.0 Hz, 1H, 6-H_b), 4.15–4.22 (m, 1H, 7-H), 4.44 (ddd, *J* = 18.2, 14.6, 4.4 Hz, 2H, 8-H_aH_b), 7.18 (s, 1H, 3-H), 7.29–7.36 (m, 1H, Ph 4-H), 7.38–7.45 (m, 2H, Ph 3,5-H), 7.81–7.87 (m, 2H, Ph 2,6-H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_C ppm: 15.3 (7-OCH₂CH₃), 46.6 (C-6), 50.4 (5-CH₂), 52.7 (C-8), 58.0 (CH₂OCH₃), 63.9 (7-OCH₂), 69.8 (CH₂OCH₃), 77.4 (C-7), 105.5 (C-3), 125.1 (Ph C-2,6), 127.8 (Ph C-4), 128.7 (Ph C-3,5), 132.4 (Ph C-1), 139.3 (C-3a), 149.1 (C-2), 161.5 (C-4). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_N ppm: −265.2 (N-5), −175.8 (N-9), −74.2 (N-1). HRMS (ESI) for C₁₈H₂₃N₃NaO₃ ([M+Na]⁺): calcd *m/z* 352.1632, found *m/z* 352.1632.

5-Allyl-7-ethoxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one 8e

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 7/2, *v/v*). Pale yellow solid, mp 113–144 °C, 77% (116 mg). *R*_f = 0.59 (*n*-hexane/ethyl acetate 1/1, *v/v*). IR (KBr) ν_{max}, cm^{−1}: 3118, 2980, 1645 (C=O), 1460, 1438, 1396, 1248, 1101, 770, 696. ¹H NMR (400 MHz, DMSO-*d*₆) δ_H ppm: 1.13 (t, *J* = 6.9 Hz, 3H, CH₃), 3.20 (dd, *J* = 15.1, 6.8 Hz, 1H, 6-H_a), 3.44 (dd, *J* = 15.1, 4.7 Hz, 1H, 6-H_b), 3.50–3.65 (m, 2H, OCH₂), 3.98 (dd, *J* = 15.1, 6.0 Hz, 1H, 5-CH_a), 4.15–4.27 (m, 2H, 5-CH_b, 7-H), 4.37 (dd, *J* = 14.6, 3.8 Hz, 1H, 8-H_a), 4.58 (dd, *J* = 14.6, 5.4 Hz, 1H, 8-H_b), 5.18–5.31 (m, 2H, CH₂-CH=CH₂), 5.81–5.93 (m, 1H, CH₂-CH=CH₂), 7.20 (s, 1H, 3-H), 7.29–7.36 (m, 1H, Ph 4-H), 7.38–7.45 (m, 2H, Ph 3,5-H), 7.81–7.87 (m, 2H, Ph 2,6-H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_C ppm: 15.3 (CH₃), 48.8 (C-6), 49.6 (5-CH₂), 52.9 (C-8), 63.9 (OCH₂), 77.1 (C-7), 105.8 (C-3), 117.8 (CH₂-CH=CH₂), 125.1 (Ph C-2,6), 127.9 (Ph C-4), 128.7 (Ph C-3,5), 132.4 (Ph C-1), 133.4 (CH₂-CH=CH₂), 139.1 (C-3a), 149.1 (C-2), 161.3 (C-4). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_N ppm: −265.6 (N-5), −176.4 (N-9), −73.9 (N-1). HRMS (ESI) for C₁₈H₂₁N₃NaO₂ ([M+Na]⁺): calcd *m/z* 334.1526, found *m/z* 334.1526.

5-Benzyl-7-ethoxy-2-phenyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-*a*][1,4]diazepin-4-one 8f

Purified by column chromatography on silica gel (*n*-hexane/ethyl acetate 3.5/1, *v/v*). Pale yellow solid, mp 115–116 °C, 72% (92 mg). *R*_f = 0.55 (*n*-hexane/ethyl acetate 3/2, *v/v*). IR (KBr) ν_{max}, cm^{−1}: 3121, 2982, 2871, 1658 (C=O), 1460 and 1440 (doublet), 1239, 1105, 771, 693. ¹H NMR (400 MHz, DMSO-*d*₆) δ_H ppm: 1.06 (t, *J* = 7.0 Hz, 3H, CH₃), 3.20 (dd, *J* = 15.2, 7.1 Hz, 1H, 6-H_a), 3.39–3.58 (m, 3H, 6-H_b, OCH₂), 3.95–4.02 (m, 1H, 7-H), 4.38 (dd, *J* = 14.7, 3.8 Hz, 1H, 8-H_a), 4.48–4.59 (m, 2H, 8-H_b, 5-CH_a), 4.88 (d, *J* = 14.7 Hz, 1H, 5-CH_b), 7.26 (s, 1H, 3-H), 7.29–7.35 (m, 2H, CPh 4-H, CH₂Ph 4-H), 7.36–7.44 (m, 6H, CPh 3,5-H, CH₂Ph 2,3,5,6-H), 7.81–7.88 (m, 2H, CPh 2,6-H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ_C ppm: 15.2 (CH₃), 49.0 (C-6), 50.4 (5-CH₂), 52.9 (C-8), 63.8 (OCH₂), 77.0 (C-7), 106.0 (C-3), 125.1 (CPh C-2,6), 127.4 (CH₂Ph C-4), 127.9 (CPh C-4), 128.1 (CH₂Ph C-2,6), 128.6 (CH₂Ph C-3,5), 128.7 (CPh C-3,5), 132.4 (CPh C-1), 137.4 (CH₂Ph C-1), 149.2 (C-2), 161.7 (C-4). ¹⁵N NMR (40 MHz, DMSO-*d*₆) δ_N ppm: −261.6 (N-5), −176.1 (N-9), −73.5 (N-1). HRMS (ESI) for C₂₂H₂₃N₃NaO₂ ([M+Na]⁺): calcd *m/z* 384.1682, found *m/z* 384.1682.

2-Benzyl-4-methoxy-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-*a*]indol-1-one 9a

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate gradient from 5/1 to 2/1, *v/v*). White solid, mp 97–98 °C, 92% (50 mg). *R*_f = 0.63 (petroleum ether/ethyl acetate 2/1, *v/v*). IR (KBr) ν_{max}, cm^{−1}: 1642 (C=O), 1541, 1457, 1421, 1099, 741. ¹H NMR (400 MHz, CDCl₃) δ_H ppm: 3.31–3.37 (m, 5H, CH₃, 3-H_aH_b), 3.68 (p, *J* = 5.2 Hz, 1H, 4-H), 4.27 (dd, *J* = 14.7, 5.2 Hz, 1H, 5-H_a), 4.33–4.41 (m, 2H, 2-CH_a, 5-H_b), 5.26 (d, *J* = 14.6 Hz, 1H, 2-CH_b), 7.11–7.16 (m, 1H, 9-H), 7.19 (s, 1H, 11-H), 7.28–7.41 (m, 7H, 7-H, 8-H, CH₂Ph 2,3,4,5,6-H), 7.66–7.71 (m, 1H, 10-H). ¹³C NMR (101 MHz, CDCl₃) δ_C ppm: 45.1 (C-5), 48.5 (C-3), 51.5 (2-CH₂), 57.0 (CH₃), 79.7 (C-4), 107.5 (C-11), 109.4 (C-7), 120.5 (C-9), 122.5 (C-10), 124.4 (C-8), 126.9 (C-10a), 127.9 (CH₂Ph C-4), 128.7 (CH₂Ph C-3,5), 128.9 (CH₂Ph C-2,6), 134.0 (C-11a), 137.4 (C-6a), 137.6 (CH₂Ph C-1), 165.0 (C=O). ¹⁵N NMR (40 MHz, CDCl₃): δ_N ppm: −259.5 (N-6), −267.8 (N-2). HRMS (ESI) for C₂₀H₂₁N₂O₂ ([M+H]⁺): calcd *m/z* 321.1598, found *m/z* 321.1596.

2-Benzyl-4-ethoxy-2,3,4,5-tetrahydro-1*H*-[1,4]diazepino[1,2-*a*]indol-1-one **9b**

Purified by column chromatography on silica gel (petroleum ether/ethyl acetate gradient from 5/1 to 4/1, *v/v*). Colorless resin, 73% (45 mg). $R_f = 0.57$ (petroleum ether/ethyl acetate 2/1, *v/v*). IR (KBr) ν_{\max} , cm^{-1} : 2360, 2341, 1641 (C=O), 1540, 1417, 1100, 741. ^1H NMR (400 MHz, CDCl_3) δ_{H} ppm: 1.14–1.20 (m, 3H, CH_3), 3.29–3.35 (m, 2H, 3- H_aH_b), 3.43–3.59 (m, 2H, OCH_2), 3.73–3.81 (m, 1H, 4-H), 4.23–4.31 (m, 1H, 5- H_a), 4.33–4.42 (m, 2H, 2- CH_a , 5- H_b), 5.22–5.30 (m, 1H, 2- CH_b), 7.10–7.21 (m, 2H, 9-H, 11-H), 7.27–7.41 (m, 7H, 7-H, 8-H, CH_2Ph 2,3,4,5,6-H), 7.66–7.72 (m, 1H, 10-H). ^{13}C NMR (101 MHz, CDCl_3) δ_{C} ppm: 15.5 (CH_3), 45.5 (C-5), 49.0 (C-3), 51.5 (2- CH_2), 64.8 (OCH_2), 77.9 (C-4), 107.4 (C-11), 109.4 (C-7), 120.4 (C-9), 122.5 (C-10), 124.3 (C-8), 126.9 (C-10a), 127.90 (CH_2Ph C-4), 128.7 (CH_2Ph C-3,5), 128.9 (CH_2Ph C-2,6), 134.1 (C-11a), 137.5 (C-6a), 137.6 (CH_2Ph C-1), 165.1 (C-1). ^{15}N NMR (40 MHz, CDCl_3): δ_{N} ppm: –259.8 (N-6), –268.6 (N-2). HRMS (ESI) for $\text{C}_{21}\text{H}_{23}\text{N}_2\text{O}_2$ ($[\text{M}+\text{H}]^+$): calcd m/z 335,1781, found m/z 335.1798.

4. Conclusions

To summarize, a regioselective strategy was developed for synthesizing ethyl 1-(oxiran-2-ylmethyl)-3-aryl-1*H*-pyrazole-5-carboxylates from easily accessible 3(5)-aryl-1*H*-pyrazole-5(3)-carboxylates. Regioselective alkylation was achieved via optimization using different bases, reaction media and temperatures. Established conditions were applied to the synthesis of novel pyrazolo[1,5-*a*][1,4]diazepin-4-one compound series via ring-opening of the oxirane with amines, and direct cyclisation sequence. Furthermore, the synthetic strategy was further applied to investigate the reactivity of ethyl 1*H*-indole-2-carboxylate and ethyl benzo[*d*]imidazole-2-carboxylate scaffolds which led to the formation of additional fused tetrahydro[1,4]diazepino[1,2-*a*]indol-1-one and tetrahydro-1*H*-benzo[4,5]imidazo[1,2-*a*][1,4]diazepin-1-one derivatives. The structures of all synthesized compounds were confirmed by detailed NMR spectroscopy and HRMS investigations.

Supplementary Materials: The following supporting information, containing ^1H , ^{13}C , ^1H - ^{15}N -HMBC, ^{19}F NMR and HRMS data, can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules27248666/s1>.

Author Contributions: Conceptualization, A.Š., A.Ž. and E.A.; Data curation, G.R., A.Ž. and E.A.; Formal analysis, K.D., M.V. and V.M. (Vít Morávek); Funding acquisition, E.A.; Investigation, K.D., M.V., V.M. (Vít Morávek) and V.M. (Vida Malinauskienė); Methodology, A.Ž.; Resources, A.Ž. and E.A.; Supervision, A.Ž. and E.A.; Validation, A.Ž. and E.A.; Writing—original draft, K.D.; Writing—review and editing, A.Š., A.Ž. and E.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Research Council of Lithuania (agreement No. S-MIP-20-60) and by the Internal Grant Agency of Palacký University (IGA_PrF_2022_012).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data that support the findings of this study are available upon request.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Sample Availability: Not available.

References

1. Taylor, R.D.; MacCoss, M.; Lawson, A.D.G. Rings in Drugs. *J. Med. Chem.* **2014**, *57*, 5845–5859. [[CrossRef](#)] [[PubMed](#)]
2. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.* **2014**, *57*, 10257–10274. [[CrossRef](#)] [[PubMed](#)]

3. McGrath, N.A.; Brichacek, M.; Njardarson, J.T. A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives. *J. Chem Educ* **2010**, *87*, 1348–1349. [[CrossRef](#)]
4. Liu, X.-H.; Yu, W.; Min, L.-J.; Wedge, D.E.; Tan, C.-X.; Weng, J.-Q.; Wu, H.-K.; Cantrell, C.L.; Bajsa-Hirschel, J.; Hua, X.-W.; et al. Synthesis and Pesticidal Activities of New Quinoxalines. *J. Agric. Food Chem* **2020**, *68*, 7324–7332. [[CrossRef](#)]
5. Schilling, W.; Zhang, Y.; Riemer, D.; Das, S. Visible-Light-Mediated Dearomatisation of Indoles and Pyrroles to Pharmaceuticals and Pesticides. *Chem. A Eur. J.* **2020**, *26*, 390–395. [[CrossRef](#)]
6. Qi, Y.; Wang, J.; Kou, Y.; Pang, H.; Zhang, S.; Li, N.; Liu, C.; Weng, Z.; Jian, X. Synthesis of an Aromatic N-Heterocycle Derived from Biomass and Its Use as a Polymer Feedstock. *Nat. Commun.* **2019**, *10*, 2107. [[CrossRef](#)]
7. Allard, N.; Aïch, R.B.; Gendron, D.; Boudreault, P.-L.T.; Tessier, C.; Alem, S.; Tse, S.-C.; Tao, Y.; Leclerc, M. Germafluorenes: New Heterocycles for Plastic Electronics. *Macromolecules* **2010**, *43*, 2328–2333. [[CrossRef](#)]
8. Al-Etaibi, A.; El-Asasery, M.; Ibrahim, M.; Al-Awadi, N. A Facile Synthesis of New Monoazo Disperse Dyes Derived from 4-Hydroxyphenylazopyrazole-5-Amines: Evaluation of Microwave Assisted Dyeing Behavior. *Molecules* **2012**, *17*, 13891–13909. [[CrossRef](#)]
9. Shams, H.Z.; Mohareb, R.M.; Helal, M.H.; Mahmoud, A.E.S. Design and Synthesis of Novel Antimicrobial Acyclic and Heterocyclic Dyes and Their Precursors for Dyeing and/or Textile Finishing Based on 2-n-Acylamino-4,5,6,7-Tetrahydrobenzo[b]Thiophene Systems. *Molecules* **2011**, *16*, 6271–6305. [[CrossRef](#)]
10. Mindt, M.; Beyraghdar Kashkooli, A.; Suarez-Diez, M.; Ferrer, L.; Jilg, T.; Bosch, D.; Martins dos Santos, V.; Wendisch, V.F.; Cankar, K. Production of Indole by *Corynebacterium Glutamicum* Microbial Cell Factories for Flavor and Fragrance Applications. *Microb. Cell Fact.* **2022**, *21*, 45. [[CrossRef](#)]
11. Yun, B.-S.; Kim, S.-Y.; Kim, J.-H.; Choi, S.; Lee, S.; Son, H.-J.; Kang, S.O. Synthesis and Characterization of Blue Phosphorescent NHC-Ir(III) Complexes with Annulated Heterocyclic 1,2,4-Triazolophenanthridine Derivatives for Highly Efficient PhOLEDs. *ACS Appl Electron. Mater.* **2022**, *4*, 2699–2710. [[CrossRef](#)]
12. Elie, M.; Renaud, J.-L.; Gaillard, S. N-Heterocyclic Carbene Transition Metal Complexes in Light Emitting Devices. *Polyhedron* **2018**, *140*, 158–168. [[CrossRef](#)]
13. Kerru, N.; Gummidi, L.; Maddila, S.; Gangu, K.K.; Jonnalagadda, S.B. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. *Molecules* **2020**, *25*, 1909. [[CrossRef](#)]
14. Costa, R.F.; Turones, L.C.; Cavalcante, K.V.N.; Rosa Júnior, I.A.; Xavier, C.H.; Rosseto, L.P.; Napolitano, H.B.; da Castro, P.F.S.; Neto, M.L.F.; Galvão, G.M.; et al. Heterocyclic Compounds: Pharmacology of Pyrazole Analogs from Rational Structural Considerations. *Front. Pharm.* **2021**, *12*, 666725. [[CrossRef](#)]
15. Karrouchi, K.; Radi, S.; Ramli, Y.; Taoufik, J.; Mabkhot, Y.; Al-aizari, F.; Ansar, M. Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review. *Molecules* **2018**, *23*, 134. [[CrossRef](#)]
16. George, N.; Jawaid Akhtar, M.; Al Balushi, K.A.; Alam Khan, S. Rational Drug Design Strategies for the Development of Promising Multi-Target Directed Indole Hybrids as Anti-Alzheimer Agents. *Bioorg. Chem.* **2022**, *127*, 105941. [[CrossRef](#)]
17. Dhuguru, J.; Skouta, R. Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents. *Molecules* **2020**, *25*, 1615. [[CrossRef](#)]
18. Murahari, M.; Mahajan, V.; Neeladri, S.; Kumar, M.S.; Mayur, Y.C. Ligand Based Design and Synthesis of Pyrazole Based Derivatives as Selective COX-2 Inhibitors. *Bioorg. Chem.* **2019**, *86*, 583–597. [[CrossRef](#)]
19. Wang, X.; Xu, Y.; Zong, Z.; Cai, J.; Chen, C.; Zhang, Q.; Sun, X.; Li, J. Design, Synthesis and Biological Evaluation of Novel 5-Methyl-2,4,5,6-Tetrahydropyrrolo[3,4-c]Pyrazole Derivatives as Potent Potassium-Competitive Acid Blockers. *Bioorg. Med. Chem.* **2022**, *64*, 116765. [[CrossRef](#)]
20. Feng, Y.; Xie, X.-Y.; Yang, Y.-Q.; Sun, Y.-T.; Ma, W.-H.; Zhou, P.-J.; Li, Z.-Y.; Liu, H.-Q.; Wang, Y.-F.; Huang, Y.-S. Synthesis and Evaluation of Pyrimidoindole Analogs in Umbilical Cord Blood Ex Vivo Expansion. *Eur. J. Med. Chem.* **2019**, *174*, 181–197. [[CrossRef](#)]
21. Purgatorio, R.; de Candia, M.; Catto, M.; Carrieri, A.; Pisani, L.; De Palma, A.; Toma, M.; Ivanova, O.A.; Voskressensky, L.G.; Altomare, C.D. Investigating 1,2,3,4,5,6-Hexahydroazepino[4,3-b]Indole as Scaffold of Butyrylcholinesterase-Selective Inhibitors with Additional Neuroprotective Activities for Alzheimer's Disease. *Eur. J. Med. Chem.* **2019**, *177*, 414–424. [[CrossRef](#)] [[PubMed](#)]
22. Conde-Ceide, S.; Alcázar, J.; Alonso de Diego, S.A.; López, S.; Martín-Martín, M.L.; Martínez-Vituro, C.M.; Pena, M.-A.; Tong, H.M.; Lavreysen, H.; Mackie, C.; et al. Preliminary Investigation of 6,7-Dihydropyrazolo[1,5-a]Pyrazin-4-One Derivatives as a Novel Series of MGLu 5 Receptor Positive Allosteric Modulators with Efficacy in Preclinical Models of Schizophrenia. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 429–434. [[CrossRef](#)] [[PubMed](#)]
23. Al-Wahaibi, L.H.; Gouda, A.M.; Abou-Ghadir, O.F.; Salem, O.I.A.; Ali, A.T.; Farghaly, H.S.; Abdelrahman, M.H.; Trembleau, L.; Abdu-Allah, H.H.M.; Youssif, B.G.M. Design and Synthesis of Novel 2,3-Dihydropyrazino[1,2-a]Indole-1,4-Dione Derivatives as Antiproliferative EGFR and BRAFV600E Dual Inhibitors. *Bioorg. Chem.* **2020**, *104*, 104260. [[CrossRef](#)] [[PubMed](#)]
24. Rashid, M.A.; Ashraf, A.; Rehman, S.S.; Shahid, S.A.; Mahmood, A.; Faruq, M. 1,4-Diazepines: A Review on Synthesis, Reactions and Biological Significance. *Curr. Org. Synth.* **2019**, *16*, 709–729. [[CrossRef](#)] [[PubMed](#)]
25. Jiménez-Somarribas, A.; Mao, S.; Yoon, J.-J.; Weisshaar, M.; Cox, R.M.; Marengo, J.R.; Mitchell, D.G.; Morehouse, Z.P.; Yan, D.; Solis, I.; et al. Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex. *J. Med. Chem.* **2017**, *60*, 2305–2325. [[CrossRef](#)]

26. Shaw, S.; Bian, Z.; Zhao, B.; Tarr, J.C.; Veerasamy, N.; Jeon, K.O.; Belmar, J.; Arnold, A.L.; Fogarty, S.A.; Perry, E.; et al. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. *J. Med. Chem.* **2018**, *61*, 2410–2421. [[CrossRef](#)]
27. Lee, T.; Christov, P.P.; Shaw, S.; Tarr, J.C.; Zhao, B.; Veerasamy, N.; Jeon, K.O.; Mills, J.J.; Bian, Z.; Sensintaffar, J.L.; et al. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. *J. Med. Chem.* **2019**, *62*, 3971–3988. [[CrossRef](#)]
28. Shen, S.L.; Shao, J.H.; Luo, J.Z.; Liu, J.T.; Miao, J.Y.; Zhao, B.X. Novel Chiral Ferrocenylpyrazolo[1,5-a][1,4]Diazepin-4-One Derivatives-Synthesis, Characterization and Inhibition against Lung Cancer Cells. *Eur. J. Med. Chem.* **2013**, *63*, 256–268. [[CrossRef](#)]
29. Bagdanoff, J.T.; Jain, R.; Han, W.; Zhu, S.; Madiera, A.M.; Lee, P.S.; Ma, X.; Poon, D. Tetrahydropyrrolo-Diazepinones as Inhibitors of ERK2 Kinase. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 3788–3792. [[CrossRef](#)]
30. Boyer, S.J.; Burke, J.; Guo, X.; Kirrane, T.M.; Snow, R.J.; Zhang, Y.; Sarko, C.; Soleymanzadeh, L.; Swinamer, A.; Westbrook, J.; et al. Indole RSK Inhibitors. Part 1: Discovery and Initial SAR. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 733–737. [[CrossRef](#)]
31. Kirrane, T.M.; Boyer, S.J.; Burke, J.; Guo, X.; Snow, R.J.; Soleymanzadeh, L.; Swinamer, A.; Zhang, Y.; Madwed, J.B.; Kashem, M.; et al. Indole RSK Inhibitors. Part 2: Optimization of Cell Potency and Kinase Selectivity. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 738–742. [[CrossRef](#)]
32. Putey, A.; Fournet, G.; Lozach, O.; Perrin, L.; Meijer, L.; Joseph, B. Synthesis and Biological Evaluation of Tetrahydro[1,4]Diazepino[1,2-a]Indol-1-Ones as Cyclin-Dependent Kinase Inhibitors. *Eur. J. Med. Chem.* **2014**, *83*, 617–629. [[CrossRef](#)]
33. Razmienė, B.; Reznicková, E.; Dambrauskienė, V.; Ostruszka, R.; Kubala, M.; Žukauskaitė, A.; Kryštof, V.; Šačkus, A.; Arbačiauskienė, E. Synthesis and Antiproliferative Activity of 2,4,6,7-Tetrasubstituted-2H-Pyrazolo[4,3-c]Pyridines. *Molecules* **2021**, *26*, 6747. [[CrossRef](#)]
34. Milišiūnaitė, V.; Arbačiauskienė, E.; Reznicková, E.; Jorda, R.; Malínková, V.; Žukauskaitė, A.; Holzer, W.; Šačkus, A.; Kryštof, V. Synthesis and Anti-Mitotic Activity of 2,4- or 2,6-Disubstituted- and 2,4,6-Trisubstituted-2H-Pyrazolo[4,3-c]Pyridines. *Eur. J. Med. Chem.* **2018**, *150*, 908–919. [[CrossRef](#)]
35. Razmienė, B.; Vojáčková, V.; Reznicková, E.; Malina, L.; Dambrauskienė, V.; Kubala, M.; Bajgar, R.; Kolářová, H.; Žukauskaitė, A.; Arbačiauskienė, E.; et al. Synthesis of N-Aryl-2,6-Diphenyl-2H-Pyrazolo[4,3-c]Pyridin-7-Amines and Their Photodynamic Properties in the Human Skin Melanoma Cell Line G361. *Bioorg. Chem.* **2022**, *119*, 105570. [[CrossRef](#)]
36. Milišiūnaitė, V.; Kadlecová, A.; Žukauskaitė, A.; Doležal, K.; Strnad, M.; Voller, J.; Arbačiauskienė, E.; Holzer, W.; Šačkus, A. Synthesis and Anthelmintic Activity of Benzopyrano[2,3-c]Pyrazol-4(2H)-One Derivatives. *Mol. Divers.* **2020**, *24*, 1025–1042. [[CrossRef](#)]
37. Milišiūnaitė, V.; Paulavičiūtė, R.; Arbačiauskienė, E.; Martynaitis, V.; Holzer, W.; Šačkus, A. Synthesis of 2H-Furo[2,3-c]Pyrazole Ring Systems through Silver(I) Ion-Mediated Ring-Closure Reaction. *Beilstein J. Org. Chem.* **2019**, *15*, 679–684. [[CrossRef](#)]
38. Secrieru, A.; O'Neill, P.M.; Cristiano, M.L.S. Revisiting the Structure and Chemistry of 3(5)-Substituted Pyrazoles. *Molecules* **2020**, *25*, 42. [[CrossRef](#)]
39. Kusakiewicz-Dawid, A.; Porada, M.; Dziuk, B.; Siodlak, D. Annular Tautomerism of 3(5)-Disubstituted-1H-Pyrazoles with Ester and Amide Groups. *Molecules* **2019**, *24*, 2632. [[CrossRef](#)]
40. Lin, R.; Chiu, G.; Yu, Y.; Connolly, P.J.; Li, S.; Lu, Y.; Adams, M.; Fuentes-Pesquera, A.R.; Emanuel, S.L.; Greenberger, L.M. Design, Synthesis, and Evaluation of 3,4-Disubstituted Pyrazole Analogues as Anti-Tumor CDK Inhibitors. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4557–4561. [[CrossRef](#)]
41. Guerrero, M.; Pérez, J.; Ros, J.; Branchadell, V.; Pellicer, E.; Sort, J.; Pons, J. Design of New N-Polyether Pyrazole Derived Ligands: Synthesis, Characterization and Regioselectivity. *Curr. Org. Synth.* **2013**, *11*, 149–155. [[CrossRef](#)]
42. Iškauskienė, M.; Ragaitė, G.; Sløk, F.A.; Šačkus, A. Facile Synthesis of Novel Amino Acid-like Building Blocks by N-Alkylation of Heterocyclic Carboxylates with N-Boc-3-Iodoazetidone. *Mol. Divers.* **2020**, *24*, 1235–1251. [[CrossRef](#)] [[PubMed](#)]
43. Matulevičiūtė, G.; Arbačiauskienė, E.; Kleizienė, N.; Kederienė, V.; Ragaitė, G.; Dagilienė, M.; Bieliauskas, A.; Milišiūnaitė, V.; Sløk, F.A.; Šačkus, A. Synthesis and Characterization of Novel Methyl (3)5-(N-Boc-Piperidiny)-1H-Pyrazole-4-Carboxylates. *Molecules* **2021**, *26*, 3808. [[CrossRef](#)]
44. Huang, A.; Wo, K.; Lee, S.Y.C.; Kneitschel, N.; Chang, J.; Zhu, K.; Mello, T.; Bancroft, L.; Norman, N.J.; Zheng, S.L. Regioselective Synthesis, NMR, and Crystallographic Analysis of N1-Substituted Pyrazoles. *J. Org. Chem.* **2017**, *82*, 8864–8872. [[CrossRef](#)] [[PubMed](#)]
45. Wright, S.W.; Arnold, E.P.; Yang, X. Steric Redirection of Alkylation in 1H-Pyrazole-3-Carboxylate Esters. *Tetrahedron. Lett.* **2018**, *59*, 402–405. [[CrossRef](#)]
46. Xu, D.; Frank, L.; Nguyen, T.; Stumpf, A.; Russell, D.; Angelaud, R.; Gosselin, F. Magnesium-Catalyzed N2-Regioselective Alkylation of 3-Substituted Pyrazoles. *Synlett* **2020**, *31*, 595–599. [[CrossRef](#)]
47. Shen, S.L.; Zhu, J.; Li, M.; Zhao, B.X.; Miao, J.Y. Synthesis of Ferrocenyl Pyrazole-Containing Chiral Aminoethanol Derivatives and Their Inhibition against A549 and H322 Lung Cancer Cells. *Eur. J. Med. Chem.* **2012**, *54*, 287–294. [[CrossRef](#)]
48. Xiong, B.; Chen, S.; Zhu, P.; Huang, M.; Gao, W.; Zhu, R.; Qian, J.; Peng, Y.; Zhang, Y.; Dai, H.; et al. Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-Pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells. *Med. Chem.* **2019**, *15*, 743–754. [[CrossRef](#)]
49. Hafez, H.N.; El-Gazzar, A.R.B.A. Synthesis and Biological Evaluation of N- Pyrazolyl Derivatives and Pyrazolopyrimidine Bearing a Biologically Active Sulfonamide Moiety as Potential Antimicrobial Agent. *Molecules* **2016**, *21*, 1156. [[CrossRef](#)]

50. Thurmond, R.L.; Beavers, M.P.; Cai, H.; Meduna, S.P.; Gustin, D.J.; Sun, S.; Almond, H.J.; Karlsson, L.; Edwards, J.P. Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S. *J. Med. Chem.* **2004**, *47*, 4799–4801. [[CrossRef](#)]
51. Schwarzkopf, J.; Sundermann, T.; Arnsmann, M.; Hanekamp, W.; Fabian, J.; Heidemann, J.; Pott, A.F.; Bettenworth, D.; Lehr, M. Inhibitors of Cytosolic Phospholipase A2 α with Carbamate Structure: Synthesis, Biological Activity, Metabolic Stability, and Bioavailability. *Med. Chem. Res.* **2014**, *23*, 5250–5262. [[CrossRef](#)]
52. Sundermann, T.; Arnsmann, M.; Schwarzkopf, J.; Hanekamp, W.; Lehr, M. Convergent and Enantioselective Syntheses of Cytosolic Phospholipase A 2 α Inhibiting N-(1-Indazol-1-yl)propan-2-yl)Carbamates. *Org. Biomol. Chem.* **2014**, *12*, 4021–4030. [[CrossRef](#)]
53. Kimura, T.; Hosokawa-Muto, J.; Asami, K.; Murai, T.; Kuwata, K. Synthesis of 9-Substituted 2,3,4,9-Tetrahydro-1H-Carbazole Derivatives and Evaluation of Their Anti-Prion Activity in TSE-Infected Cells. *Eur. J. Med. Chem.* **2011**, *46*, 5675–5679. [[CrossRef](#)]
54. Althaus, J.; Hake, T.; Hanekamp, W.; Lehr, M. 1-(5-Carboxyindazol-1-yl)propan-2-Ones as Dual Inhibitors of Cytosolic Phospholipase A2 α and Fatty Acid Amide Hydrolase: Bioisosteric Replacement of the Carboxylic Acid Moiety. *J. Enzym. Inhib. Med. Chem.* **2016**, *31*, 131–140. [[CrossRef](#)]
55. Saddique, F.A.; Zahoor, A.F.; Faiz, S.; Naqvi, S.A.R.; Usman, M.; Ahmad, M. Recent Trends in Ring Opening of Epoxides by Amines as Nucleophiles. *Synth. Commun.* **2016**, *46*, 831–868. [[CrossRef](#)]
56. Meninno, S.; Lattanzi, A. Epoxides: Small Rings to Play with under Asymmetric Organocatalysis. *ACS Org. Inorg. Au* **2022**, *2*, 289–305. [[CrossRef](#)]
57. Wang, C.; Luo, L.; Yamamoto, H. Metal-Catalyzed Directed Regio- and Enantioselective Ring-Opening of Epoxides. *Acc. Chem. Res.* **2016**, *49*, 193–204. [[CrossRef](#)]
58. Meninno, S.; Lattanzi, A. Organocatalytic Asymmetric Reactions of Epoxides: Recent Progress. *Chem.-A Eur. J.* **2016**, *22*, 3632–3642. [[CrossRef](#)]
59. Wang, C. Electrophilic Ring Opening of Small Heterocycles. *Synthesis* **2017**, *49*, 5307–5319. [[CrossRef](#)]
60. Li, D.; Wang, J.; Yu, S.; Ye, S.; Zou, W.; Zhang, H.; Chen, J. Highly Regioselective Ring-Opening of Epoxides with Amines: A Metal- A Nd Solvent-Free Protocol for the Synthesis of β -Amino Alcohols. *Chem. Commun.* **2020**, *56*, 2256–2259. [[CrossRef](#)]
61. Tan, N.; Yin, S.; Li, Y.; Qiu, R.; Meng, Z.; Song, X.; Luo, S.; Au, C.-T.; Wong, W.-Y. Synthesis and Structure of an Air-Stable Organobismuth Triflate Complex and Its Use as a High-Efficiency Catalyst for the Ring Opening of Epoxides in Aqueous Media with Aromatic Amines. *J. Organomet. Chem.* **2011**, *696*, 1579–1583. [[CrossRef](#)]
62. Hattori, G.; Yoshida, A.; Miyake, Y.; Nishibayashi, Y. Enantioselective Ring-Opening Reactions of Racemic Ethynyl Epoxides via Copper–Allenylidene Intermediates: Efficient Approach to Chiral β -Amino Alcohols. *J. Org. Chem.* **2009**, *74*, 7603–7607. [[CrossRef](#)] [[PubMed](#)]
63. Malhotra, S.V.; Andal, R.P.; Kumar, V. Aminolysis of Epoxides in Ionic Liquid 1-Ethylpyridinium Trifluoroacetate as Green and Efficient Reaction Medium. *Synth. Commun.* **2008**, *38*, 4160–4169. [[CrossRef](#)]
64. Hansen, T.; Vermeeren, P.; Haim, A.; van Dorp, M.J.H.; Codée, J.D.C.; Bickelhaupt, F.M.; Hamlin, T.A. Regioselectivity of Epoxide Ring-Openings via S_N2 Reactions Under Basic and Acidic Conditions. *Eur. J. Org. Chem.* **2020**, *2020*, 3822–3828. [[CrossRef](#)]
65. Wu, Y.; Tang, C.; Rui, R.; Yang, L.; Ding, W.; Wang, J.; Li, Y.; Lai, C.C.; Wang, Y.; Luo, R.; et al. Synthesis and Biological Evaluation of a Series of 2-(((5-Akly / Aryl-1H-Pyrazol-3-yl)Methyl)Thio)-5-Alkyl-6-(Cyclohexylmethyl)-Pyrimidin-4(3H)-Ones as Potential HIV-1 Inhibitors. *Acta Pharm Sin. B* **2020**, *10*, 512–528. [[CrossRef](#)]